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ABSTRACT
Several pathologies associated with the bladder have wide impacts on society.
Overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC/PBS) are chronic
urological conditions characterized by pain, urinary frequency, and urgency with or without
urinary incontinence. The estimated prevalence of OAB and IC/PBS is more than 34 million
people in the U.S. alone. The American Cancer Society estimated a total of 68,810 new bladder
cancer cases and 14,100 deaths from bladder cancer in the U.S. in 2008. Treatment options
include oral medications, transdermal patches and intravesical instillations of therapeutic
solutions. Direct intravesical instillation is considered an effective option, especially for those
who remain refractory to oral and transdermal formulations due to intolerable side effects and
skin irritations, respectively. Intravesical treatment, however, requires repeated instillations due
to rapid drug voiding by urination, and the frequent urinary catheterizations involve risk of
urinary infection and patient discomfort.
An alternative, site-specific local delivery approach was created using a reservoir-based
drug delivery device. This novel passive device was designed to release drug in a pre-
determined manner once inside the bladder. The device also possesses a retention feature to
prevent accidental voiding. The device can be implanted into and retrieved from the bladder by
a non-surgical cystoscopic procedure. In vivo tests using lidocaine, a local anesthetic used for
IC/PBS treatment, showed that a sustained and local treatment to the bladder can be achieved
with the device. The lidocaine bladder tissue concentration was found to be a thousand-fold
higher than the lidocaine plasma concentration at three and six days in a rabbit model. The
device approach has the potential to achieve localized therapy to the bladder while minimizing
side effects. Future studies may use the device for other therapeutic agents in the treatment of
OAB, IC/PBS, and bladder cancer.
Thesis Committee
Prof. Michael J. Cima (Thesis Advisor)
Prof. Ioannis V. Yannas (Thesis Reader)
Prof. Robert S. Langer (Committee Chair)
Acknowledgements
I am grateful to my thesis supervisor, Professor Michael Cima for his guidance and
generous support throughout my research project. His endless curiosity about the unknown and
passion for the research has motivated me to make greater efforts. Your enthusiasm and
excitement have always impressed me. I am also indebted to Professor Robert Langer and
Professor loannis Yannas for their support and priceless advice with their supreme expertise.
I would like to thank Dr. Alison Hayward, Katie Madden, Sylvia Lesnikowski, Chris
Autieri, and Catrina Wong for being helpful, patient, and supportive of me during the many
hours in the animal facilities.
I would like to thank the members of Convergence Products Research Research
Laboratory at MIT: Grace Kim, Hong Linh Ho Duc, Karen Daniel, Christophoros Vassiliou,
Yoda Patta, Noel Elman, Dan Wesolowski, Alex Scott, Byron Masi, Irene Tobias, Yibo Ling,
Lenny Rigione, and Barbara Layne. In particular, Grace Kim thankfully proofread my thesis
carefully. I also should mention three summer UROP students, who contributed to the research:
Mario Castillo, Lydia Marshall, and Daniel Macaya. I would also like to extend my appreciation
and apologize to the experimental animals. Their sacrifice contributed to scientific knowledge
and experience I gained throughout this project.
Finally, I would like to thank my family and friends for their support, understanding, and
encouragement in my many moments of stress. I thank my parents for their emotional support
and encouragement they have given me throughout the years. I also thank my friends, Yeunwoo
Cho, Jongmin Shim, Jungik Kim, Hyungsuk Lee, Chiwon Kim, Sunho Park, and Kyung-yon Na.
Table of Contents
Chapter 1 Introduction .................................................. 11
1.1 Background and m otivation ............................................................ ....................... 11
1.1.1 Interstitial cystitis/painful bladder syndrome (IC/PBS) and overactive bladder
(O A B ) ........................................................................................................................... 1 1
1.1.2 Superficial bladder cancer................................................. 13
1.2 T hesis objectives ......................................................................................................... 14
Chapter 2 Device fabrication and in vitro drug release studies .......... 15
2.1 D esign concept ....................................................................... ................................ 15
2.2 D evice fabrication m ethods...................................... .............................................. 17
2.3 In vitro drug release studies ......................................................... 25
2.3.1 In vitro release study with chondroitin sulfate C ...................................... 25
2.3.2 In vitro release study with lidocaine ....................................... .......... 28
2.4 O sm otic drug release .................................. ....... ..................................... .............. 30
Chapter 3 Retention feature of the intravesical drug delivery device .... 35
3.1 C oncept........................................ ........................................................... . ..... 35
3.2 Analysis of the deformation of the elastic ring device................................ ..... 36
Fr 2
3.2.1 Nodal elastica (0 <-- < 0.3148) ....................................... .......... 37
2EI
Fr 2
3.2.2 Oval shape (0.3148 < - <1.3932) ...................................... .......... 37
2EI
Fr2
3.2.3 Peanut shape (1.3932 <- ) ..................................... .... ............. 38
2EI
3.2.4 Numerical plot for the deformation of elastic circular ring ............................ 39
3.3 C ollapse-resistive design .............................................................................................. 4 1
3.4 Design approach for low modulus wires................................................................... 45
Chapter 4 Topical absorption of lidocaine into the urothelium ........... 47
4.1 O ne com partm ent m odel .............................................................. .......................... 47
4.2 Drug distribution model for drug absorption in the bladder .................................... 49
4.2.1 Drug concentration in the urine................................................................ 49
4.2.2 In vitro drug distribution model in the bladder ........................................ 51
4.2.3 In vivo drug distribution model in the bladder ...................................... ... 53
4.3 In vitro lidocaine absorption study with rat bladder ......................................... 55
Chapter 5 In vivo lidocaine exposure studies in a rabbit model .......... 62
5.1 Intravesical instillation of lidocaine solution ........................................ ........ 62
5.2 Implantation of intravesical drug delivery device............................... ........ 63
5.3 Measurement of the lidocaine concentration in blood and bladder .......................... 67
5.3.1 B lood sam ples ................................................................. ............................. 67
5.3.2 Bladder tissue samples ........................................................ 68
5.4 B iodistribution of lidocaine....................................................................................... 69
5.5 Im plantation in the sem inal vesicle ......................................... ............................... 76
5.6 Encrustation and low calcium diet .................................................... 78
5.7 L idocaine toxicity......................................................................................................... 84
Chapter 6 Design scheme for tubular drug release device ................. 86
6.1 Basic equations for tubular osmotic pump ........................................ .......... 86
6.2 Design of tubular osm otic pum p ............................................................................... 91
6.2.1 Device made of polymer tube ................................................... 93
6.2.2 Device with sheath for minimizing water permeation .................................... 94
Chapter 7 Conclusions and future work ................................... 98
7.1 Sum m ary ...................................................................................................... 98
7.2 Future directions........................................................................................................... 99
References .............................................................. 100
Appendix ................................................................. 105
Appendix 1. MATLAB code for the deformation of elastic circular ring ....................... 105
Appendix 2. Control rabbit diet ....................................... 110
Appendix 3. Low calcium rabbit diet ................................................... ........................... 111
6
List of Figures
Figure 1. A loop-shaped device with multiple drug release orifices. Undeformed shape of the
device after being deployed in the bladder (left). Deformed shape during cystoscopic
implantation through the urethra (right). ......................................... ................ 16
Figure 2. A device containing multiple reservoirs and orifices (left). Cross-section view of
elastic polymer tubing with spheres inserted for compartmentalization of reservoirs (right).
.................................................................................................... ..................  1 7
Figure 3. Cast form of chondroitin sulfate C (CSC). (Left) SEM picture of cast CSC (Courtesy
of Lenny Rigione and Hong Linh Ho Duc). (Right) macro image of cast CSC.............. 18
Figure 4. Crystallized lidocaine in a cylindrical form. ...................................... .......... 19
Figure 5. Silicone tubes (0.012" x 0.025", ID x OD) containing crystallized lidocaine pieces.
Each tube was sealed with stainless steel microballs at both ends. Stainless steel wires
inserted at the ends were used to fix the tube in a vial for in vitro release study. Laser
drilled orifice is located in the middle between two microballs for each tube .................. 20
Figure 6. Silicone tubes (0.012" x 0.025", ID x OD) filled with crystallized lidocaine pieces.
First three tubes from the top have an additional polyurethane sheath to minimize water
permeation at the covered locations. Laser drilled orifice is located at the middle between
two microballs for each tube ......................................... 21
Figure 7. Various types of prototype device made of silicone tubing. (Top left) device with
medical silicone adhesive. (Top Right) device with monofilament nylon suture. (Bottom)
device with multiple reservoirs and orifices, SEM images of laser drilled hole, and
microscopic image of inserted cast rod and microball into the silicone tubing ................ 22
Figure 8. Shaped nitinol wires after heat treatment (left). Drug filled silicone tube connected
with a shaped nitinol wire (right). Shaped nitinol structure has a superelastic property..... 23
Figure 9. Completed form of the device. Both ends of the arms can have platinum wires wound
around the tips (optional), and the ends are embedded with UV curable epoxy to make the
tips blunt and sm ooth ............................................................................................................ 24
Figure 10. Sequence of the device compression. The resistance increases once the three sub-
circles overlap. The device returns to the original shape immediately after the compression
is removed . ................................................................ 25
Figure 11. Device with ruby disc inserted (left), and the microscopic image of the orifice disc
inserted side (right). The outer diameter of the orifice disc is 0.06" and the thickness is
0 .0 1" ....... ................................................................................................................................ 2 6
Figure 12. Device with the orifice disc inserted (10 im diameter) when immersed in water (left).
Inflated tube due to hydrostatic pressure build-up inside the device (right). The outer
diameter of the orifice disc is 0.06" and the thickness is 0.01" ......................................... 27
Figure 13. The effect of the orifice size on in vitro release for chondroitin sulfate C (CSC) at
room tem perature. ................................................................................................................. 28
Figure 14. In vitro lidocaine release curves at 37 'C with the device of silicone tube with a laser-
drilled hole (50 lm diam eter). .............................................................................................. 30
Figure 15. Laser drilled orifice on a silicone tube wall ....................................... ........ 31
Figure 16. Tubular osmotic pump immersed in bath medium................................ ....... 34
Figure 17. Elastic ring under compression (three different regimes are indicated). Relationship
between compressive force and displacement ...................................................................... 40
Figure 18. The relationship between dimensionless spring constant and compression........... 41
Figure 19. Compression test for a pretzel shape nitinol spring................................... ....... 43
Figure 20. Compression of can circular arc (courtesy of Jongmin Shim) .................................... 44
Figure 21. One-compartment model for transient bladder tissue concentration....................... 48
Figure 22. The response of the bladder tissue concentration depending on the treatment type ... 49
Figure 23. Semi-infinite composite model for the drug diffusion in the bladder in vitro.......... 53
Figure 24. Semi-infinite composite model for the drug diffusion in the bladder in vivo .......... 55
Figure 25. Procedure of inverting the rat bladder: (top) Sprague Dawley rat bladder, about 1 cm
in length. (Middle) Inverted bladder on a cotton tipped applicator. (Bottom) The inverted
bladder knotted by suture........................................... .................................................... 57
Figure 26. The effect of pH on the absorption of lidocaine in rat bladder for 1 hour and 1 day.
The bladder samples were placed in 1% lidocaine solution (0.06 tCi/mL)...................... 59
Figure 27. Lidocaine tissue concentration-time profiles for 10-5% and 1% lidocaine solutions
(n=3 for each pH and each time point. Error bars indicate the standard deviation of three
sam ples). ..................................................... 61
Figure 28. The device implantation sequence by the catheter-stylet system ................................ 65
Figure 29. Radiographs of implanted devices. (Top row) Immediately after implantation,
(Middle row) 2 days after implantation, (Bottom row) 9 days after implantation. Left
column is when the animal was in the right lateral recumbent position and right column is
when the animal was in the supine position.............................................................. 66
Figure 30. Representative typical standard curve for standard dilutions of plasma (0, 0.5, 1, 2, 4,
and 8 ng/mL). Cubic spline curve (top) and semi-log graph (bottom) ............................. 68
Figure 31. In vivo results for lidocaine plasma concentration. Lidocaine plasma concentration
for the instillation treatment (dotted lines) and the device treatment (solid lines). Errors bars
represent the standard deviation for the duplicate samples for ELISA assay .................... 70
Figure 32. In vivo results for lidocaine plasma concentration. The scale of the vertical is modified
from Error! Reference source not found. to better show the results from the device treatment.
Errors bars represent the standard deviation for the duplicate samples for ELISA assay.... 71
Figure 33. Lidocaine tissue concentration ([tg/g). Device residence time and drug payload are
indicated. Errors bars represent the standard deviation for the samples from multiple
animals or from multiple positions in the bladder. ..................................... ......... 73
Figure 34. Correlation between lidocaine plasma concentration and tissue concentration. Errors
bars represent the standard deviation for the tissue samples from multiple positions in the
bladder or for the duplicate plasma samples for ELISA ...................................... ..... 74
Figure 35. Lidocaine concentration of tissue and urine. Device implantation time and drug
loading are indicated. Errors bars represent the standard deviation for the tissue samples
from multiple positions in the bladder or for the duplicate plasma samples for ELISA ..... 75
Figure 36. Genital organs of a male New Zealand White rabbit. The bladder is shown in the left
and the penile urethra in the right. ........................................................... ....................... 77
Figure 37. Porcine male reproductive system (Diagram reproduced here with permission from Dr.
Charlotte L. Ownby, College of Veterinary Medicine, OKlahoma State University,
Stillw ater, O K ) .......................................................... ..................................................... 77
Figure 38. Lidocaine plasma concentration with the device implanted in the seminal vesicle. The
device shape was that of the one at top right in Figure 7 ................................................... 78
Figure 39. The effect of the dietary calcium level on the plasma calcium level. The range for
calcium excretion for the rabbit is about 45-60% while other mammals excrete less than 2%
of ingested calcium in the urine [63]. .................................... ....................... 79
Figure 40. Rabbit urine in 15 mL centrifuge tube. Urine was placed vertically, not centrifuged,
and precipitated calcium carbonate is shown as sediment ....................................... 79
Figure 41. Encrusted placebo device without drug release reservoir. The device was implanted
in the bladder for 9 weeks. Radiographs (a) in the supine position and (b) in the right lateral
recumbent position. (c) The device before implantation. (d) The retrieved device from the
bladder at 9 weeks after implantation. The calcium encrustation on the device can be seen
in Radiographs. ............................................................. 81
Figure 42. Rabbit diet pellets. (Left) control rabbit diet (LabDiet"). (Right) low calcium diet
(TestD iet" ).................................................... 82
Figure 43. The device with encrustation after 3 day implantation in the rabbit bladder: (left) the
device from the rabbit with the control diet, (middle) the device from the rabbit with low
calcium diet for 2 weeks, (right) the device from the rabbit with low calcium diet for 4
w eeks ............................................... 83
Figure 44. Relationship of signs and symptoms of local anesthetic-induced central nervous
system (CNS) toxicity to plasma concentrations of lidocaine [77]. .................................. 85
Figure 45. In vitro release of lidocaine HCI in water at 37 C ........................................ 91
Figure 46. Dependency of sheath length and sheath covered portion on loop diameter and tube
inner diameter for a= 10 and b=50 (payload: 100 mg) ......................................... ............. 96
Figure 47. Dependency of sheath length and sheath covered portion on loop diameter and tube
inner diameter for a=20 and b=200 (payload: 400 mg) .......................................... 97
List of Tables
Table 1. Specifications for the devices used for in vitro lidocaine release study ...................... 29
Table 2. Dimensionless force and deflection in three regiems ............................................... 39
Table 3. Young's modulus and design parameters for nitinol and other low modulus materials. 46
Table 4. Three different types of device ....................................................... 90
Table 5. Specifications for two examples of devices for human application ............................ 94
Chapter 1 Introduction
1.1 Background and motivation
1.1.1 Interstitial cystitis/painful bladder syndrome (IC/PBS) and overactive bladder (OAB)
Interstitial cystitis/painful bladder syndrome (IC/PBS) and overactive bladder (OAB) are
chronic urological conditions characterized by pain, urinary frequency, urgency with or without
urinary incontinence, and variable degrees of sexual dysfunction. IC/PBS affects about 1 million
people in the US alone with 90% of them women. The quality of life of IC/PBS patients is
comparable to end stage renal failure. The estimated prevalence of OAB in the US is about 33
million with the occurrence rising with age [1-4]. Patients with OAB symptoms tend to restrict
their social activities to avoid public embarrassments, and the social isolation caused by OAB
often leads to depression symptoms [5, 6].
Recent studies concerning IC/PBS have suggested that an inhibition of normal bladder
epithelial cell proliferation leads to a loss of epithelial barrier integrity with subsequent exposure
of sensory nerve cells in the bladder wall to toxic and irritating urinary constituents [7, 8].
However, there is no known cure for IC/PBS, and so current treatments are targeted to relieve
symptoms. A major challenge in the treatment of IC/PBS is to deliver the appropriate
medication to the bladder. The FDA-approved oral medication for IC/PBS, pentosan polysulfate
sodium (PPS), is thought to help replenish the defective and denuded bladder wall. However, the
bioavailability of PPS is as low as 3% [9], and recent studies have reported questionable results
about the significant benefit for IC patients provided by orally administered PPS [10].
Oxybutynin is a frequently prescribed medication for OAB although orally administered
oxybutynin often causes side effects. A large pre-systemic, first-pass metabolism of oxybutynin
results in an oral bioavilability of only 6%. Oxybutynin metabolites appear to contribute largely
to dry mouth [11, 12], the most common side effect with oxybutynin, which is unfortunate for
the patients because their desire to drink is countered by a desire to manage their urinary
incontinence. A transdermal patch (OXYTROL) has been recently introduced to avoid first-pass
metabolism although skin irritation leads to its low acceptance rate [13]. Skin irritation is due to
the high concentration of oxybutynin required to achieve sufficient flux through the skin. The
plasma level of the active metabolite N-desethyloxybutynin, the main cause of dry mouth, to its
parent compound oxybutynin was 1.3:1 compared to 11.9:1 for an orally administered dose.
Thus, an alternative route of administration can reduce the production of oxybutynin metabolites
and, thus, can decrease the incidence of dry mouth.
Intravesical instillation of therapeutic solutions for bladder disorders is considered an
effective treatment option especially to those who remain refractory to oral formulations due to
intolerable side effects. A measured amount of drug solution is instilled into the bladder through
a catheter, and the drug solution is held inside the bladder usually less than an hour before
patients void the solution. The procedure is performed every week or repeated as needed. If the
bladder is the site of the problem as in the case of IC/PBS, intravesical administration of drug
solutions can diminish undesirable side effects which are commonly found in oral drug treatment
for bladder disorders.
A recently introduced treatment for IC/PBS is intravesical delivery of a lidocaine solution
[14, 15]. The solution contains lidocaine, heparin, and sodium bicarbonate and demonstrated
immediate symptom relief as well as the sustained relief of pain and urgency with 90%
effectiveness [15]. This "therapeutic cocktail" has been shown to be effective in managing pain
in IC/PBS patients, but its limited duration requires frequent intravesical boluses of drug, such as
three treatments per week for two weeks. While the site-specific, local delivery approach of
intravesical instillation is desirable, frequent intravesical instillation accompanied by urinary
catheterization should be avoided to minimize the risk of infection and patient discomfort.
1.1.2 Superficial bladder cancer
The American Cancer Society estimates that 68,810 men and women will be diagnosed
with and 14,100 will die of cancer of the urinary bladder in 2008 [16]. 70-80% of bladder
tumors are non-muscle invasive tumors [17]. Recurrence following endoscopic resection of the
superficial disease will occur in 50 to 70% of these cases if not followed by chemotherapy.
Chemotherapeutics are administered in solution as an intravesical bolus. The patient must retain
the bolus for a period of about an hour as the majority of the agent is eliminated during urination.
The procedure is repeated weekly for five to six weeks. Agents include mitomycin C, ethoglucid,
thiotepa, doxorubicin, epirubicin, and valrubicin [18]. The short exposure times require that the
drug concentration be made as high as possible in the intravesical formulation. In vitro
experiments with human bladder cancer cell lines have shown that concentration and exposure
time are equally important. That is, the same cytotoxicity was achieved for mitomycin C,
thiotepa, epodyl, and adriamycin when the exposure was 30 minutes for a given concentration or
120 minutes at one fourth the concentration [19]. Thus, the normal chemotherapeutic doses of
20 to 30 mg could be significantly lowered if the exposure time could be lengthened to days
from the current thirty to sixty minutes. In addition, there is clinical evidence that current
exposures are not optimized and should be increased. Patients receiving six weekly 40 mg
mitomycin C administrations had twice the recurrence-free fraction at five years than patients
receiving 20 mg doses [20].
1.2 Thesis objectives
The goal of this research is to develop a drug delivery device that can replace treatments
requiring frequent intravesical instillations of drug solutions for patients with IC/PBS and OAB.
The proposed approach is to fabricate passive, non-resorbable release devices that can be
deployed and retrieved by a conventional catheterization, which is a simple nonsurgical
outpatient procedure. The size of the device should be small enough to minimize patient
discomfort and have a retention feature to avoid accidental voiding of the device. The objectives
pertaining to developing an intravesical drug delivery device are as follows:
1) Fabricate a device that can be non-surgically implanted into the bladder (Chapter 2).
2) Perform in vitro drug release studies to determine parameters affecting drug release rate
(Chapter 2).
3) Investigate device retention features to prevent its accidental voiding (Chapter 3).
4) Characterize drug absorption into the bladder wall (Chapter 4).
5) Perform in vivo drug exposure studies (Chapter 5).
6) Obtain design equations for the device for human application (Chapter 6).
Chapter 2 Device fabrication and in vitro drug release studies
2.1 Design concept
The drug delivery device was designed to fulfill multiple criteria. Primarily, the device
must be inserted into and retrieved from the bladder through the urethra cystoscopically. This
means that the device must pass through a narrow tubular path. The outer diameter of the
urethral catheter for adult humans is about 14-16 Fr (4.7-5.3 mm). The device should also
reduce patient discomfort and trauma to the bladder. The size of the device was minimized. The
outer surface of the device, furthermore, should be soft and smooth without sharp edges or tips.
It is desired that the device has a density less than urine or water so that it can float inside the
bladder to keep the device from touching the sensitive trigone region near the bladder neck. The
device should have a retention feature to avoid its accidental voiding during urination over the
treatment period. A design that features a material with a certain elastic limit and modulus
allows the device to be introduced into the bladder in a collapsed shape but then spring open
once inside the bladder. A sufficient elastic modulus would prevent the device from collapsing
into a linear shape and accidentally being expelled from the bladder during urination or
contraction of the detrusor muscle.
One of the simplest design options is a loop-shaped device shown in Figure 1 where the
device has multiple drug release orifices. The feasibility of a loop-shaped device depends on the
availability of such elastic, biocompatible materials. A, large deformation will occur at two
folded spots during cystoscopic insertion, and the device will return to its original loop shape
after insertion for the retention of the device in the bladder.
The device may contain both multiple orifices and multiple reservoirs to release more
than one type of drug. Orifices can be generated by laser ablation or drilling on a polymeric tube
wall. Figure 2 shows a device with multiple reservoirs and orifices. Spherical objects can be
inserted into the tubing to create partitioned reservoirs. The elastic nature of the tubing material
enables the insertion of the snugly-fitted spherical objects, whose diameter is slightly larger than
the inner diameter of the tubing to create a seal between two adjacent reservoirs. The
mechanism of drug release from the device is that of an osmotic pump [21]. Water (or urine)
permeates through the walls of the polymer tube (semi-permeable membrane) and pushes drug
particles or solution out through a micro-orifice on the polymer wall. The surface area, wall
thickness, and water permeability of the tube are key factors for the drug release.
Figure 1. A loop-shaped device with multiple drug release orifices. Undeformed shape of the device after
being deployed in the bladder (left). Deformed shape during cystoscopic implantation through the urethra
(right).
2.2 Device fabrication methods
A solid form of drug, instead of liquid form, was loaded into the device to maximize the
payload within a given volume. Chondroitin 6-sulfate or chondroitin sulfate C (CSC) is a
sulfated glycosaminoglycan (GAG), and the site of sulfation is carbon 6 of the GalNAc sugar.
CSC is used for the treatment of IC/PBS [22-26]. CSC (Chondroitin 6-sulfate sodium salt from
shark cartilage, Sigma-Aldrich, St. Louis, MO) was cast into a cylindrical form by a solution
filling and evaporation method. Silicone is highly permeable to water as the scale decreases [27,
28]. Thin-walled silicone tube (0.012"x 0.020", ID x OD, Invotec International, Inc.) was first
filled with CSC aqueous solution, and then the solution was allowed to dry at room temperature
while keeping the tube straight. The length of the tube filled with CSC solution decreased while
evaporation of water proceeded. Figure 3 shows the final product obtained after the evaporation
procedure. The length of the cast CSC depends on the initial length of tube filled with CSC
solution and the solution concentration.
Figure 2. A device containing multiple reservoirs and orifices (left). Cross-section view of elastic polymer
tubing with spheres inserted for compartmentalization of reservoirs (right).
.. ............... .............
Figure 3. Cast form of chondroitin sulfate C (CSC). (Left) SEM picture of cast CSC (Courtesy of Lenny
Rigione and Hong Linh Ho Duc). (Right) macro image of cast CSC.
Lidocaine and lidocaine hydrochloride (HC1) were both purchased from Sigma-Aldrich
(St. Louis, MO). Lidocaine base form has a very low solubility (- 4 mg/mL) in comparison to
that of lidocaine HCI (-680 mg/mL) [29]. The HCI form was used to make aqueous lidocaine
HCI solution. Tube filling followed by evaporation was performed as described for CSC. The
length of the tube filled with the lidocaine solution decreased while water evaporated, but a solid
lidocaine cast was not obtained at the end. Lidocaine remained as a gel form instead of a
solidified form. Crystallization step for lidocaine was further introduced to the saturated
lidocaine after the evaporation step [30]. A lidocaine seed crystal was inserted into either end of
the tube after evaporation, and the tube was stored at 4 'C. Crystallized lidocaine was brittle
compared with CSC, resulting in crystallized pieces that were less than 1 cm (Figure 4).
; I 1'' I -- -~
Figure 4. Crystallized lidocaine in a cylindrical form.
In vitro drug release studies were performed using silicone tube of 1 cm or 2 cm in length.
The same size tube as the one where drug was cast or crystallized was used for each drug. A
single piece of cast CSC was inserted into the silicone tube since long cast CSC were produced.
A longer length of CSC rod was cut to 1 cm or 2 cm with a razor blade. Several pieces of
crystallized lidocaine, however, were inserted into the tube to fill 1 cm or 2 cm in length. One
piece of CSC rod or several pieces of lidocaine rods were pre-weighed before insertion into the
tube. A drug release orifice on each silicone tube was generated by laser ablation (Spectralytics
Inc., MN, and Teosys Engineering, MD) before inserting the drug rod piece(s). Figure 5 shows
silicone tubes filled with crystallized lidocaine pieces. Lidocaine pieces were inserted piece by
piece using tweezers and stainless steel wire. Stainless steel microballs with a diameter of
0.024" (SS316, Salem Specialty Ball Company, Inc., CT) were inserted to seal both ends. The
elastomeric nature of the silicone tube enables the balls larger than inner diameter of the tube to
snugly fit into the tube. The laser drilled orifice with a diameter of 50 Plm was positioned in the
middle of two sealing balls. Additional stainless steel wires (Stainless Steel 304V Wire .022"OD,
Small Parts, FL) were inserted to fix the tube in a vial for in vitro release study. UV curable
epoxy (Medical Device, 1-20542, Dymax Corporation, CT) with UV system (ADAC Cure Spot
50 Systems, Dymax Corporation, CT) was used to anchor the drug loaded tube to a vial.
Figure 5. Silicone tubes (0.012" x 0.025", ID x OD) containing crystallized lidocaine pieces. Each tube was
sealed with stainless steel microballs at both ends. Stainless steel wires inserted at the ends were used to fix
the tube in a vial for in vitro release study. Laser drilled orifice is located in the middle between two
microballs for each tube.
Polyurethane tube (Micro-Renathane, 0.025" x 0.040" (ID x OD), Braintree Scientific,
Inc., MA) was used to cover some portion of the silicone tube to reduce water permeation of the
device. Half the length of 2 cm length device was covered with the polyurethane tube. Two 0.5
cm sheaths made of polyurethane tubes were used for a 2 cm device shown in Figure 6. Silicone
tubes shown in Figure 6 do not have stainless steel wires inserted at the ends. Two sheathes
were located near the orifice to prevent the drug located far from the orifice from being isolated
during the process of the water permeation and drug release. The results from in vitro release
studies using the drug-loaded silicone tubes will be shown in the next section.
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Figure 6. Silicone tubes (0.012" x 0.025", ID x OD) filled with crystallized lidocaine pieces. First three tubes
from the top have an additional polyurethane sheath to minimize water permeation at the covered locations.
Laser drilled orifice is located at the middle between two microballs for each tube.
The drug-loaded silicone tube was used to construct the intravesical drug delivery device.
Figure 7 shows various types of prototype device such as a device with medical silicone adhesive
(Silastic Medical Adhesive, silicone type A, Dow Coming, MI), device with monofilament nylon
suture (Ethilon, monofilament nylon, size 1, 4.0 metric, Ethicon, inc.), and device connected by
stainless steel ball with a diameter of 1/32". The device with suture was tested for preliminary in
vivo toleration test with a rabbit. The device, however, was urinated out soon after implantation.
This result indicated that a device should be equipped with better retention feature to avoid
accidental voiding.
Mi bl
Micro balls
Figure 7. Various types of prototype device made of silicone tubing. (Top left) device with medical silicone
adhesive. (Top Right) device with monofilament nylon suture. (Bottom) device with multiple reservoirs and
orifices, SEM images of laser drilled hole, and microscopic image of inserted cast rod and microball into the
silicone tubing.
Superelastic wire was introduced to improve the retention of the device. Superelastic
nitinol wire (0.009" O.D., Small Parts Inc. FL) was formed into a pretzel shape by heat treatment.
A new shape was imparted by restraining the wire in the pretzel shape and heating it to a
temperature above 500 "C for over five minutes. More details about the shape will be discussed
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in Chapter 3. Figure 8 shows the shaped wires after heat treatment and the drug loaded silicone
tube connected to the superelastic structure made of nitinol wire.
Figure 8. Shaped nitinol wires after heat treatment (left). Drug filled silicone tube connected with a shaped
nitinol wire (right). Shaped nitinol structure has a superelastic property.
Additional steps were required to complete device fabrication for in vivo studies, and
Figure 9 shows a completed form of the device. End portions of the nitinol structure were cut,
and the silicone tube (0.020" x 0.037", ID x OD, Invotec International, Inc.) was covered at
either end. UV curable epoxy was used to smoothen both ends of the device before covering with
the silicone tube. Platinum wire (Platinum wire, 0.010" O.D., Omega Engineering, Inc., CT) can
be optionally wound around either end of the nitinol wire structure before applying UV curable
epoxy (Figure 9) to improve radio-opacity for x -ray imaging although nitinol itself shows radio-
opacity to some extent.
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Figure 9. Completed form of the device. Both ends of the arms can have platinum wires wound around the
tips (optional), and the ends are embedded with UV curable epoxy to make the tips blunt and smooth.
The device functions as a spring due to the superelastic nitinol while still having a
smooth and soft outer surface due to the outer silicone surface. Figure 10 shows the sequence of
the device compression. The device is designed to have more resistance to the compression as
the compression proceeds to prevent the collapse of the device due to detrusor muscle
contraction during urination. Measurement of the device spring constant during compression
will be discussed in Chapter 3. The device returns to the original shape after compression once
the load is removed.
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2.3 In vitro drug release studies
2.3.1 In vitro release study with chondroitin sulfate C
A spectrophotometric 1,9-dimethylmethylene blue (DMMB)-based GAG assay was used
to quantify concentrations of CSC for in vitro release study [31, 32]. A dye solution was made
by adding 5.5 mg of DMMB powder (1,9-Dimethyl-Methylene Blue, Sigma-Aldrich, MO) to
500 mL of 0.05 M sodium acetate trihydrate (CH 3COONa - 3H20, pH 4.75) buffer. The dye
solution was stored at room temperature in an airtight brown glass bottle no longer than 1 month.
20 pL of samples from in vitro CSC release study in water as well as standard dilutions (0 to 80
g/mL) were transferred to each well in a 96-well plate, and 200 L of the dye solution was
added to each well. The optical density of each well was measured using a micro-plate reader
(SpectraMax plus384, Molecular Devices) at a wavelength of 520 nm.
The effect of orifice size on the drug release rate was investigated with the use of
precision ruby orifices (synthetic ruby orifice, Bird Precision, Inc., MA). The ruby orifices offer
extremely round and sharp edges hole with tight tolerance (+0.0002"/-0.0000") compared with a
hole generated on the silicone tube wall by laser ablation. Ruby discs with drug release orifices
Figure 10. Sequence of the device compression. The resistance increases once the three sub-circles overlap. The
device returns to the original shape immediately after the compression is removed.
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with a diameter of 10, 15, 20, or 50 um and silicone tubes with a laser-ablated hole of 50 or 150
m were compared. Figure 11 shows silicone tube (0.012"x 0.020", ID x OD, Invotec
International, Inc.) with a ruby disc and a microball (diameter of 0.024", SS316, Salem Specialty
Ball Company, Inc., CT) inserted at either end. A CSC rod with a length of 1 cm was loaded
between the ruby disc and the microball. The ruby disc was tightly inserted into the silicone tube,
and only the portion near a hole was exposed (Figure 11).
Figure 11. Device with ruby disc inserted (left), and the microscopic image of the orifice disc inserted side
(right). The outer diameter of the orifice disc is 0.06" and the thickness is 0.01".
Excessive hydrostatic pressure buildup inside the silicone tube device can cause the
inflation or swelling of the device. The swelling of the tube was observed for a device with 10 or
15 jtm holes when in vitro CSC release experiments were performed. The device with smaller
drug release hole, such as 10 or 15 pim orifice, requires sufficient pressure in order to push the
liquid through a narrow orifice at the ruby disc. The position where the disc is inserted is most
susceptible to the swelling in the tube since the position was stretched once the ruby orifice was
inserted. Figure 12 shows the tube before swelling and after swelling when the ruby orifice with
10 pm diameter hole was submerged in water.
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Figure 12. Device with the orifice disc inserted (10 lm diameter) when immersed in water (left). Inflated
tube due to hydrostatic pressure build-up inside the device (right). The outer diameter of the orifice disc is
0.06" and the thickness is 0.01".
The size of the drug release orifice affected the drug release rate as shown in Figure 13.
The excessive swelling of the tube may create sudden leakage of the drug around the inserted
disc (15 gtm orifice), or even lead to the expulsion of the orifice from the silicone tube (10 gtm
orifice). The CSC release experiment with 10 gm orifice was stopped when the disc orifice was
detached from the tube. The drug release was retarded during the swelling of the tube because
ingress of water through silicone tube wall is not balanced by the outflow through the orifice.
Accumulated water ingress inside the tube is responsible for the swelling of the device as
observed in Figure 12. The device with 150 jpm orifice, in contrast, released CSC quickly such
that most of the drug was released after 24 hours. The release profile with 50 gtm orifice overall
showed a first-order drug release rate.
2.3.2 In vitro release study with lidocaine
High-performance liquid chromatographic (HPLC) was used to quantify lidocaine in the
samples from in vitro lidocaine release study [33, 34]. The HPLC system was an Agilent Chem
Station 1100 Series (Agilent Technologies, CA) equipped with an autosampler (G1313A),
quaternary pump (G1311A), and diode array detector (G1315B) set at 214 nm. The column
(gBondapak C18, 10 pm, 3.9 x 150 mm, WAT086684, Waters Corporation, MA) was
maintained at 30 'C by a HPLC column heater (ThermaSphere TS-130, Phenomenex Inc., CA)
and used with a mobile phase composed of 10% acetonitrole and 90% water buffered with
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0.01M KH 2PO 4 adjusted to pH 2.1 with phosphoric acid. The flow rate was 1 mL/min, and the
injection volume was 50 VL. Retention time was about 8 minutes.
Silicone tube devices with a laser drilled orifice, as shown in Figure 5 and Figure 6 , were
used for in vitro lidocaine release study. 50 jim was chosen as the orifice diameter to obtain a
first-order release profile based on the results from in vitro CSC release experiment. In vitro
lidocaine release curves using four different types of devices are shown in Figure 14.
Specifications for each type of device are shown in Table 1. Two different sizes (inner diameter
x outer diameter) of silicone tubes were used, and both were purchased from Invotec
International, Inc. There was no orifice with the control device, and it was observed that the
microballs were pushed outward due to internal hydrostatic pressure buildup. Type 'III' device
had a polyurethane sheath as shown in Figure 6 to reduce water permeation. Detailed discussion
and interpretation about the in vitro release results are found in Chapter 6.
Table 1. Specifications for the devices used for in vitro lidocaine release study
I.D. x O.D. Tube wall thickness
Type Payload Total tube length (cm)
(inches) (inches)
I 2 mg 0.012 x 0.025 0.0065 2
II 1 mg 0.012 x 0.025 0.0065 1
III 2 mg 0.012 x 0.025 0.0065 2 (half covered with sheath)
IV 4 mg 0.020 x 0.037 0.0085 2
Control 4 mg 0.020 x 0.037 0.0085 2 (no orifice)
4000
3500
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Figure 14. In vitro lidocaine release curves at 37 OC with the device of silicone tube with a laser-drilled hole
(50 lpm diameter).
2.4 Osmotic drug release
The mechanism of drug release from the device is that of the elementary osmotic pump
(EOP). Felix Theeuwes described theoretical and experimental aspects of the EOP [21]. The
EOP delivers drugs at a controlled rate through an orifice by water permeation through a semi-
permeable membrane. Our device has a laser-drilled orifice on the silicone tube wall. The
orifice was generated by an ultraviolet excimer laser micromachining system. The orifice can be
considered as a circular channel with a length equal to the tube wall thickness (h). The radius of
the orifice (R) varies depending on the amount of the ablated silicone material from the tube. A
S1)2 mg load, 2cm, 0.012"x0.025" (IDxOD) (n=3)
- 1--l) 1 mg load, 1 cm, 0.012"xO0.025" (IDxOD) (n=3)
~- - - - -- - - - - - - - - - - ::::...........- :
straight channel shape is considered here for the simplicity of the analysis although there is some
taper in the orifice between the outer and the inner surface of the tube. One example is that an
entrance hole on the outer tube wall has a diameter of 55 Pim and an exit hole on the inner wall
has a diameter of 45 jtm.
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Figure 15. Laser drilled orifice on a silicone tube wall
Flow through a laser drilled orifice is considered here as circular Hagen-Poiseuille flow.
Outward volume flow rate (Q,,,) can be expressed as
Q = 27urdr = R 4  dp 4  Ap8p dx 8p h
where u is the flow velocity along the orifice length and pt is the viscosity of the dispensed drug
solution. Ap is hydrostatic pressure difference across the orifice channel. The solvent influx
through the silicone tube wall is governed by the osmotic pressure difference ( AIl) and
hydrostatic pressure difference (Ap) between inside and outside of the tube. Inward volume
flow rate (Q,) through the semi-permeable silicone tube wall can be expressed as
A
Q, = , L(oA - Ap)h
where A is the silicone tube surface area for solvent ingress; Lp and or are the mechanical
permeability and the reflection coefficient, respectively. It is assumed that the orifice area (7nR2)
is sufficiently small compared with the overall silicone tube surface area (A). The osmotic
pressure difference (AAH) between the inside and outside of the tube can remain constant as long
as there is solid undissolved drug in the device reservoir, and the concentration of the drug inside
the tube is considered as the solubility of the drug. The inward volume flow rate is equal to
outward volume flow rate when the silicone tube does not deform due to excessive hydrostatic
pressure buildup, and so we get
Q.,t = n
The hydrostatic pressure and osmotic pressure difference can be expressed as
Ap = AH
I+ --
8jtALJ
and
r ALp ) AH
Q = 8h81pALP h
+ R 4
The expression for the drug release rate (dm/dt) is described by
dm A
dm = Q, C = L (o-AH - Ap)Cdt h
where C is the concentration of drug in the fluid dispensed through the orifice. The density
inside the drug reservoir is initially that of the loaded drug, and solvent or water permeation
occurs until the reservoir is completely filled with water.
The osmotic pressure difference (AlH) can be much greater than the hydrostatic pressure
difference (Ap) as the delivery orifice increases (AHI >> Ap or R>> (8pALp/ c) ). The
expressions for the drug release rate, in this case, reduces to
dm A
- kAI C
dt h
where the constant k replaces LpC . Excessive hydrostatic pressure buildup inside the tube can
deform elastomeric silicone tube. Swelling of the device was observed for the in vitro
experiments with small ruby orifice. The increase of the device reservoir volume makes the
assumption invalid that the inward volume flow rate is the same as the outward volume flow rate
through the orifice. The outward volume flow rate, in this case, is smaller than the inward
volume flow through the tube wall surface. One of the solutions to the problem of distension of
the device is to increase the orifice size until the drug delivery by diffusion through the orifice is
significant.
Our silicone tube device is an EOP with tubular geometry. A tubular osmotic pump with
a length of 2L is shown in Figure 16. Tubular osmotic pump immersed in medium such as water
or urine allows solvent or water permeation through the semi-permeable tube wall. Multiple
orifices can be placed on the tube wall. Provided that the hole size of each orifice is within the
range required for osmotic drug release where the drug diffusion through the orifice is minimized,
multiple orifices will lower the pressure difference along the orifice channel. The outward and
inward volume flow rates for the device with multiple orifices with the condition of dominant
osmotic pressure difference (AH >> Ap) can be expressed respectively as
rR4
Qou = ~8 h8,u 
and
A
, A kAIh
where N is the number of the orifices on the tube wall. The condition for the non-deformed
device (Qout = Qin) gives
8,uAk
NR4
where the pressure difference across the orifice channel (Ap) is inversely proportional to the
number of orifice (N).
Figure 16. Tubular osmotic pump immersed in bath medium
Surrounding
medium
Flow direction
orificel
-' I Ir'"i rAtPr .-I~" ~Y
I A
X-O
i - , - -ml I
1~S~P~i~i~
I
I
I4
X=L
Chapter 3 Retention feature of the intravesical drug delivery device
3.1 Concept
The preliminary in vivo test using the device made of silicone and suture materials
revealed that a retention feature is important for the device to stay in the bladder without
accidental expulsion or voiding over the designed treatment period. The detrusor muscle in the
wall of the bladder contracts the bladder during urination. The contraction of the detrusor
muscle combined with the hydrodynamic force during urination can expel the device before the
completion of the treatment, which is undesirable. There is a possibility that the device may
block the bladder neck or urethra during accidental voiding of the device. The implantable
device for the bladder, therefore, should have a retention feature, which includes the proper
design and material properties such as elastic modulus and elastic limit.
A closed loop or ring design is one of the simplest design options, but a ring-shaped
device must undergo large deformation when it is implanted into the bladder cystoscopically. A
cystoscope is a specialized telescope passing through the urethra to observe and manipulate
inside the bladder. Cystoscopic implantation of the device requires the device to pass through
the narrow working channel of the cystoscope. Most cystoscopes for adults are about 5 mm in
diameter. The diameter of the working channel is about 2.4 mm or smaller. The ring-shaped
device must be folded in half for cystoscopic insertion, and the two folded locations must go
through large deformation. The device must then return to the ring shape after insertion into the
bladder without collapsing into a linear shape to prevent accidental voiding of the device. The
feasibility of a loop-shaped device depends on the availability of biocompatible materials with
the proper elastic properties satisfying the conditions described above.
3.2 Analysis of the deformation of the elastic ring device
The analysis of the deformation of an elastic ring subject to two equal and opposite radial
loads is a useful tool to find key design parameters and their relationships. The deformation of
elastic circular rings was studied by R. Frisch-Fay when deformation is restricted in the initial
plane of the ring [35]. Implicit solutions were obtained by the theory of non-linear deflections
for three regimes depending on the magnitude of the radial loads. The relationship between
force and deflection was numerically plotted (using MATLAB) in this section and the numerical
codes are added in Appendix. Figure 17 shows the closed ring under two equal and opposite
radial forces. Depending on the magnitude of the forces, the deformed shape can be in the
regime of 1) the nodal elastica [36], 2) oval, or 3) peanut shape (Figure 17). The analytic method
and approach for each regime varies because the associated geometry for analysis changes
depending on the degree of deformation. The full analyses are lengthy and found in two papers
by Frisch-Fay. Only key equations necessary for numerical analysis will be presented here. The
following notation is used throughout this section:
F(p,# ) = [dp/ 1-p 2 sin 2 p] : Legendre's incomplete elliptic integral of the first kind
K(p) = f[dp/ 1- p 2 sin 2 ] : Legendre's complete elliptic integral of the first kind
/2
E(p) = 2 1- p 2 sin 2 pdq : Legendre's complete elliptic integral of the second kind
F : Compression force
A : Vertical deflection of the ring
r : Radius of unloaded circular ring
Fr 2
3.2.1 Nodal elastica (0 <-- <0.3148)
2EI
This regime is when the analytical method of the nodal elastica, instead of the undulating
elastica, is used [36]. This regime physically corresponds to a relatively small deformation of
the ring. The range for
4 -2 C
2 F(p 1, )-=0.3148 .xp 4
expressed respectively as
Fr 2  4 -
this regime can be expressed as 0 << F2(p = 1, ) where
2EI 4
The compression force and the corresponding deflection can be
(3.1)2E 4p2t2F = 2 - 2 - ( p,
2r 2 4
and
A= EIr - 2 p 2 7 A =r -E - -- F
IP 4
(3.2)
where 0 < p <1. The force and the deflection is correlated by the parameter p.
Fr 23.2.2 Oval shape (0.3148 <-- < 1.3932)
2EI
Oval shape of the ring is obtained when the initially circular ring is deformed by the
compression lateral force until no point of inflection exists. The range where the ring becomes
4 -2 ) Fr 2  4 2 1
oval shape can be expressed as F2(p = ,-)< < (p= where
A 4 2EI 22
4 - 4
2 F2(p =1, ) = 0 .3 148 and 2K2(p= )=1.3932.) )4 The expression for the compression
force and the corresponding deflection is respectively,
2EI 4 -2
F= 2 2 (p, 0)j
and
A= r - 2E(p,0)-F(p, ) ]
F
where 0B = sin-'(1/ p) and / i < p <1.
Fr23.2.3 Peanut shape (1.3932<--)
2EI
(3.3)
(3.4)
The ring assumes a peanut shape when the ring deforms further from the oval shape. The
range for this 4 -
1 Fr2
regime is 2 (p = ) < Fr
72 t 2 2EI
4 -2
where K2 1(p )=1.3932
V2
expression for the compression force and the corresponding deflection can
respectively as
F= 2 2 L-(p ) -(p,)]2
and
A = r- - [4E(p)- 2K(p) - 2E(p, B) + F(p, B)]
w F
where O = sin-'(1/ p) and 1/,[ < p <1.
The
be written
(3.5)
(3.6)
3.2.4 Numerical plot for the deformation of elastic circular ring
The compression force (F) and the deflection (A) are correlated by parameters p and
0, for each regime. The solution for each regime can be expressed using dimensionless force
(Fr2 / EI) and deflection (A/r) (Table 2).
Table 2. Dimensionless force and deflection in three regiems
Regime Dimensionless force (Fr 2 / El ) and deflection (A /r)
Fr 2 8 p2
El i7 4
Nodal elastica
A r2E 2 2
- -E p, - -p p,
0 < -- < 0.6297 r Fr2 p 4 p
El
(0<p<l)
Fr2 8 -2
-
= 
-- (p,)
El i 2
Oval shape
A 2El E(pp, O
Fr 2  -- Fr2 (p,B)-(p,0.6297 < - < 2.7864 r
El
(O = sin-' (1/ f2p)and 1/-2 < p <1)
Fr 2  8 2 Z (p ) - (ph )] 2
El i7
Peanut shape
A 2 El --Fr2= 1- 2 4E(p)-2K(p)-2E(p,)+ F(p,,)
Fr2  r 1 Fr22.7864 < -
EI
(O = sin (1/ 2p)and 1/ -2< p <1)
The three regimes are plotted altogether using MATLAB in Figure 17. The range of
compressive displacement is set to less than a radius of the initial elastic ring. Dimensionless
force (Fr 2 / EI) and deflection (A / r ) represent vertical and horizontal axis, respectively.
Figure 18 shows slope or dimensionless spring constant with respect to dimensionless
compression.
3.3 Collapse-resistive design
The device should stay in the bladder over the treatment period without accidental
voiding. The bladder is not a static environment for the device since the bladder contracts its
volume and the urination causes a hydrodynamic force that may lead to the accidental expulsion
of the device. Preliminary in vivo toleration test with rabbits shows that the device made of
silicone tube and monofilament nylon suture was urinated out soon after the device implantation
(Figure 7, Top right). The proper retention feature is, therefore, crucial for the device to reside in
the bladder until the cystoscopic retrieval of the device. A unique structure with a shape is
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Figure 18. The relationship between dimensionless spring constant and compression.
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similar to a pretzel was introduced to the device as a retention feature. The pretzel shape was
chosen as its resistance to compression increases upon compression of the two sub-circles. The
initial period of bladder contraction during urination causes a very small or negligible resistance
force against the detrusor muscle because only the largest arch will be involved in the
deformation. Further contraction of the detrusor muscle makes the two sub-circles overlap, and
the total three arches will resist the compression. This feature prevents the collapse of the device
structure to avoid accidental voiding. The device can immediately return to its original shape
once the compression is removed due to the superelastic property of nitinol.
Mechanical compression testing of the pretzel-shaped spring was performed using an
Instron 5542 with 10 kN load cell equipped with Merlin software. (Instron, MA). The spring
was formed using the same superelastic nitinol wire that was used in the device. Video capturing
of the compression event was recorded during the compression test. Figure 19 shows the
experimental result showing the relationship between the compressive force and displacement.
The initial spacing was 2.9 cm and the compression speed was 2 mm/min. There are three points
(A,B,and C) indicated in the plot, and the corresponding instantaneous images are shown below
the plot. Bilinear behavior was observed over the compression. A sudden slope increase was
observed when the three arches overlapped. The slope or spring constant for the region A-B is
about 0.0037 N/mm while that for the region B-C is about 0.057 N/mm. There is 15.4 times
slope increase from the region A-B to B-C. The single arch contributed to the resistance to the
compression from the point A to B. All three arches started to contribute to the resistance when
the compression reached the point B. The pretzel spring returned to the original shape when the
compressive load was removed after the compression reached the point C. The spring can return
to the initial shape after large deformation because of the super elasticity of nitinol.
The relationship between force and displacement for a small deflection can be obtained
using Castigliano's second theorem [37]. Figure 20 shows a circular arc under compressive
force F with its radius of r, its central angle of p , and its flexural rigidity El. Vertical
displacement at the top free end is denoted as A and the bottom end is assumed to be fixed in
place as in the compression test shown above. The strain energy U is expressed as
U= + cosp--s 3in p (3.7)
2EI 2 2
The deflection is obtained from Castigliano's second theorem as:
CU Fr3 ( 3.A= I o+-cosp--sin I (3.8)
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Figure 19. Compression test for a pretzel shape nitinol spring
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or in the dimensionless form:
Fr2
EI
(3.9)(2p + op cos - 3 sin) r
Eq. (3.9) for a semicircle ( r= ) is further reduced to:
Fr2  2 A
EI x r
The spring constant ( dF / dA) is therefore
dF 2EI E d 4
dA ;r' 32 r3
where the moment of inertia (1) for the wire with a diameter d is substituted by rd 4 / 64.
(3.10)
(3.11)
F F
q=
F F
Figure 20. Compression of can circular arc (courtesy of Jongmin Shim)
The sudden slope increase in Figure 19 can be explained by Eq. (3.11). The ratio of the
slope for the region B-C (three arches) to the initial slope for the region A-B (single arch) is
(dF / dA)Bc
(dF / dA)AB
3 /(1.7cm) 3 
-149
11/ (2.9cm)3
(3.12)
where 1.7 cm is the diameter when the three arcs start to overlap, and 2.9 cm is the initial
diameter of the single arc. Compression test showed that about 15 times slope increase from the
region A-B to region B-C, and Eq. (3.11) predicts the result well although simple linear elastic
analysis is used. The superelasticity of nitinol is advantageous in extrapolating the result from
the simple linear analysis for small deflection regime to predict the behavior for the large
deflection regime.
3.4 Design approach for low modulus wires
Analysis for a elastic ring and an arc reveals a proportional equation for the spring
constant (F/A) as
F El Ed4
A r3  r3  (3.13)
and the spring constant for the retentive body with multiple windings has the equation as
F Ed4- n (3.14)
A r
where n is the number of multiple windings. Nitinol was used for the retentive body, but an
elastomer with low modulus can be used, still having a spring constant comparable to that of the
nitinol retentive body. The elastomeric retentive body is especially useful when the device is
made of completely biodegradable rubber such as poly(glycerol-sebacate) (PGS) [38].
According to Eq. (3.14) for a spring constant, the small Young's modulus E for low modulus
elastomers can be compensated for by one or more of the following: decreasing the radius of an
arc, increasing the wire diameter, and having multiple and/or overlapped circles or windings.
Reducing the radius of an arc by a factor of two and increasing a wire diameter by a factor of two
can significantly increase a spring constant by a factor of 27 or 128. Examples of a spring
constant are tabulated below for some low modulus elastomers. Relative magnitude of a spring
constant for each material was evaluated with respect to nitinol device using Eq. (3.14).
Parameters for each material were selected to show a spring constant comparable to the nitinol
device. Other combinations of parameters can also used to obtain a desirable spring constant.
Table 3. Young's modulus and design parameters for nitinol and other low modulus materials.
Material
Nitinol Polyurethane Silicone PGS
Parameter
Young's modulus (E) 30 GPa 25 MPa [39] 2.41 MPa 1.7 MPa
Diameter (d) 0.2286 mm 1 mm 1.2 mm 1.2 mm
Arc radius (r) 1.5 cm 1 cm 0.75 cm 0.76 cm
Number of coils (n) 1 1 2 3
SF/A
Relative spring constant F 1 1.03 0.96 0.99(F / A ) )
Chapter 4 Topical absorption of lidocaine into the urothelium
4.1 One compartment model
The urinary bladder has several important functions: storage of an adequate volume of
urine, facilitation of bladder emptying at appropriate time intervals, and protection of smooth
muscle and nerve from exposure to urine. This last function is largely the role of the urothelium
or transitional epithelium, the epithelial lining that covers the bladder wall and urinary tract such
as the ureter and urethras. Urothelium has three layers: umbrella cell stratum, intermediate cell
stratum and basal cell stratum. A layer of umbrella cells is closest to the bladder lumen and the
glycosaminoglycan (GAG) layer covers the surface of the umbrella cells. It is widely believed
that a defect in the GAG layer causes the symptoms of interstitial cystitis [ 15, 40, 41]. Lamina
propria, located below a layer of basal cells, contains blood capillaries and nerves. Irritating
urine constituents may leak through the urothelium, causing tissue inflammation and sensory
nerve depolarization [42].
Absorption of drug into the bladder can be simplified by a one-compartment model to
obtain the tissue concentration-time profiles. This model only considers the average drug
concentration in the bladder tissue. Figure 21 shows the one-compartment model for the bladder.
The average concentration of bladder tissue is denoted as C(t), which is a time-dependent
variable. The effective first-order rate constant for absorption of drug is referred to as ka. The
hybridized first-order rate constant describing absorption into the systemic circulation,
degradation, and metabolism is represented by kd. The concentration of drug solution in contact
with bladder is denoted as f(t). The exposure time of drug solution to the bladder is determined
by the residence time, t,, of the instilled drug solution The equation for the bladder tissue
concentration C(t) is given by:
dC
d=ka f(t)-kdC, C(0) = 0 (4.1)dt
where f(t) = (0 < ) and fo is assumed to be constant. The analytical solution of Eq.
O (t > tr)
(4.1) is obtained as:
kafo (1- e - kd ' )  (0 < t < t)
C(t) = kd (4.2)
ka (e-kd(-t -e -  (t > tr)
ka Bladder kd
f(t) ------ -------
c(t)
Figure 21. One-compartment model for transient bladder tissue concentration
The response of the bladder tissue concentration is different depending on the treatment
type. Figure 22 shows two treatment types, A) intravesical instillation of drug solution, and B)
the intravesical drug delivery device. The intravesical instillation features a short duration of
drug exposure to the bladder determined by the drug retention time (tr) and a high concentration
of drug solution (fo). The treatment of the intravesical device is characterized by extended drug
exposure and relatively low drug concentration in the bladder. The results for the two treatments
are quite different as illustrated in Figure 22. Based on Eq.(4.2), the treatment type A will show
a high peak of tissue concentration followed by its rapid drop after the voiding of the instilled
solution. Bladder tissue concentration with the device will slowly reach the low magnitude
plateau, but the low concentration will be sustained over an extended period of time.
4.2 Drug distribution model for drug absorption in the bladder
4.2.1 Drug concentration in the urine
Intravesical instillation of cytotoxic agents into the bladder is a common treatment used
for patients with superficial bladder cancer. There have been several attempts to find a
mathematical model for drug absorption into the bladder during instillation treatment [43-47].
Mathematical models for the drug absorption during intravesical treatment can be used to
develop intravesical drug delivery system. The drug concentration in urine during instillation
treatment is time dependent due to urine production. The drug concentration can be found by
solving the following equations as described in [48]:
f(t)
C(t)
A: intravesical instillation of solution
KB: extended release by device
time
Figure 22. The response of the bladder tissue concentration depending on the treatment type
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dA = -kA (4.3)
dt
where A = A(t) = V(t)C(t) and V(t) = + Ves, + kot. A(t), C(t), and V(t) are the amount and
concentration of drug, and volume of the bladder contents at time t, respectively; the first-order
absorption rate constant is denoted as k,. The urine volume, V(t), consists of the volume of
instilled drug solution (Vs), residual urine volume (Vres), and the volume added by urine
formation with the urine production rate (k0 ). Solving Eq. (4.3) gives
V(O)C(O) DoseC(t) = exp(-kt) = exp(-kt) (4.4)
V(t) V(t)
This model assumes that the rate of drug decease in the bladder is proportional to the amount of
drug present in the bladder [48]. An alternative model for the drug concentration present in urine
can be developed by assuming that the drug absorption is proportional to the surface area of the
bladder wall multiplied by the drug urine concentration. Introducing a spherical geometry of the
bladder (Area oc volume2/3 ) and the first-order absorption rate constant ( k2 ), we get the
differential equation as
dA= 
_k2V 213C (4.5)
dt
where A(t) = V(t)C(t) and V(t) = V + V,,s + kot . The solution to Eq. (4.5) is expressed as:
C(t)= V(O)C(O) exp 3k 2 ((V es k) 2 3 - 2/3) (4.6)(t) V(t)exp -2ke s ) (4.6)
4.2.2 In vitro drug distribution model in the bladder
The bladder wall can be considered as a thin diffusion barrier (the urothelium) covering
the deeper capillary-perfused tissues of the lamina propria and muscle layers [46]. Systemic
removal or capillary drainage in the capillary-perfused tissues can be neglected in the in vitro
setting of drug absorption into the bladder. The urothelium thickness is about 200 pm for the
human bladder while that for dog and rabbit bladder tissues is about 50 [tm [44]. The simplest
model for in vitro drug distribution in the bladder is to view the bladder as a semi-infinite
medium at the following initial and boundary conditions:
C=Co = KC, at x=0, t>0 (4.7)
C=O at x>0, t=0 (4.8)
where C and C, are the tissue drug concentration in depth x at time t, and the luminal drug
concentration in the bladder; K is the partition coefficient for the drug bladder tissue to the
luminal solution. The luminal solution concentration can remain constant if the total amount of
drug absorbed into the bladder is negligible compared with the total drug present in the luminal
solution in the donor chamber of the diffusion cell. The drug tissue concentration for the semi-
infinite model can be expressed using the complementary error function as
C = KCerfcJ j (4.9)
where D is the drug diffusion coefficient in the bladder tissue. The total drug amount absorbed
in the tissue through unit area of the bladder wall surface (M, ) is obtained as
M D dt = 2C Dt (4.10)1aCx= p'
where Co = KC,.
Biphasic diffusion behavior in the bladder tissue is typically observed for drug tissue
distribution [43]. The diffusion behavior in the urothelium is different from the rest of the
deeper bladder wall. The decrease of drug tissue concentration in the urothelium is steeper than
that in the tissues below the urothelium. The biphasic behavior introduces different drug
diffusion coefficients for urothelium and the rest of the bladder tissue. Then, the drug
distribution in the bladder wall can be viewed as diffusion in a semi-infinite composite medium
with the surface layer (urothelium) having diffusion properties different from the deeper bladder
tissue layers in Figure 23. The initial and boundary conditions are the same as Eq. (4.7) and Eq.
(4.8) (zero initial concentration and constant surface concentration). The conditions at the
interface is
C,=C 2 atx=l (4.11)
ac ac,D = D2  2 at x =1 (4.12)ax ax
where subscript 1 and 2 indicate the properties in the urothelium and in the deeper tissues,
respectively, and 1 is the thickness of the urothelium. The solution for the semi-infinite
composite medium is given by [49, 50]:
C1 (x,t)= C, a" erfc (2n)l + x (2n + 2)1 - xC, (x, t) = Co a erfc -
-  
aerfc for 0 <x < 1 (4.13)
n=0 2 Dt 2 Drt1
2kCo -'a, e (2n +1)1+ k(x -1)
C2 (X, ) (2n+l - 1 for x 1l (4.14)k+1 n=0 2- t
The total amount of drug absorbed through unit
area of the bladder surface at x=O during time t is M,, give by
M,(t) = 2Co S1+ 2 a" exp(-n 21 2 / Dit) -41C o j na"erfc
n=1 n=l
(4.15)
and for sufficiently large times, we have an approximate expression for M, as
t 1a 4a
V r, 1(I - a) (I - a)
(4.16)
where k = JDD 2 and a = (1-k)/(l+k) . We can see from Eq. (4.10) and (4.16) that M, is
proportional to t 1/ 2 .
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Figure 23. Semi-infinite composite model for the drug diffusion in the bladder in vitro
4.2.3 In vivo drug distribution model in the bladder
In vivo drug absorption in the bladder is different from in vitro absorption because
systemic drug absorption occurs in the lamina propria and muscular layers where capillaries are
Urine
C,
x=O
where k = /D / D 2 and a=(1 - k)/(1+k).
perfused and drug can be removed via the blood [46, 51]. Systemic drug absorption in the
lamina propria and muscular layers can be considered by introducing microscopic permeability
coefficient (p) and surface area of the capillaries (a) as in Figure 24. The steady solution
(ac / at = 0) can be achieved as follows:
Ci = C (Co C)x for 0<xl (4.17)
C 2 =C b (C l -Cb)exp - (x-l) for x1 (4.18)
where Co = KC, ; C, is the concentration at the interface between the urothelium and the
submucosa (lamina propria); Cb is the plasma drug concentration in blood vessels. The drug
tissue concentration in the urothelium declines linearly with increasing depth. There is an
exponential decrease of the drug tissue concentration in the lamina propria and muscular layers
due to the removal of drug by capillaries. The biphasic behavior for drug tissue concentration-
depth profiles is caused by the existence of capillaries perfused in the tissues. The concentration
difference between the tissue and the perfusing blood determines the amount of systemic drug
removal as in Figure 24. There is a limitation to obtain an analytical solution for in vivo drug
distribution model. Numerical simulation for kinetic model of drug distribution after intravesical
instillation was studied by Grabnar et al [46]. The model parameters used in their study were
obtained under in vitro conditions, and so the numerical simulation has a limitation of precisely
depicting in vivo conditions [45]. However, despite its limitations, the urine and tissue
pharmacokinetic models can not only offer an insight into the relationship between treatment
conditions and parameters but also can provide the basis to design future intravesical drug
delivery system.
Lamina propria and muscular layers
c , C2  pa(C2 -C,p)
-D 0C 1  a D a2Cat 2  
-
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Figure 24. Semi-infinite composite model for the drug diffusion in the bladder in vivo
4.3 In vitro lidocaine absorption study with rat bladder
Lidocaine absorption in vitro into urothelium was investigated with rat bladders (Pel-
Freez Biologicals). The effect of urine pH and absorption time were also studied. A lidocaine
solution was made with artificial urine (Surine Negative, Dyna-Tek Industries, Inc.),
radiolabeled lidocaine hydrochloride [carbonyl- 14C] (50-60 mCi/mmol, M.W.=270.9, American
Radiolabeled Chemicals, Inc.), and lidocaine hydrochloride monohydrate (Sigma-Aldrich Co.).
A 1% solution has the radioactivity of 0.06 tCi/mL, and a 10-5% solution has the radioactivity of
0.02 [tCi/mL. Radiolabeled lidocaine solution was made with ethanol and the concentration is
0.1 pCi/gtL. 20 mL 1% lidocaine solution having the radioactivity of 0.06 jtCi/mL was made
with 200 mg of non-radioactive lidocaine, 12 gpL of radioactive lidocaine solution. 20 mL 10-5%
lidocaine solution having the radioactivity of 0.02 jiCi/mL was made as follows. First, 10
gtg/mL solution was made with 50 gtg (100 tL) of radioactive lidocaine and 5 mL of artificial
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urine. Then, ImL from the previous 10 [pg/mL solution was added to 9 mL of artificial urine (1
Cpg/mL solution). Finally, 0.1 pg/mL (10-5% ) solution was obtained by adding 2 mL of the 1
pg/mL solution to 18 mL of artificial urine. The pH of synthetic urine was adjusted with HCI
1.ON solution (Sigma-Aldrich Co.) or 8.4% Sodium bicarbonate (Sigma-Aldrich Co.) to obtain
solution pH ranging from 4.0 to 8.5. Lidocaine hydrochloride did not dissolve at pH levels
higher than 8.5.
Rat bladders were inverted to expose the urothelium (inner lining of the bladder) and the
inverted neck was closed by suture (Ethilon, 4-0, Ethicon, Inc.) to avoid having the lidocaine
solution come in contact with the outer lining of the bladders. Inverting the bladder was done by
tweezers and a plastic cotton applicator. First, the opening of rat bladder (Pel-Freez Biologicals,
Sprague-Dawley rats, 56002-2, 7-8 weeks old, mixed gender) is stretched out by tweezers. Then,
the bladder portion opposite to the opening is pushed by plastic cotton tipped applicator so that
the bladder can be inverted. The bladder tissue over applicator is further stretched out to make
sure that the bladder is completely inverted. Once inverted, a knot is made with suture as close
to the bladder opening as possible. The applicator is withdrawn from the bladder once the first
suture knot is made. The first knot is further tighten up after the withdrawal of the applicator,
and two extra knots are made to ensure that drug solution does not leak into the bladder when it
is immersed in the solution. Figure 25 shows the procedure of inverting the rat bladder. A leak
test was performed with trypan blue saline solution (Sigma-Aldrich Co.). Bladders were placed
in the solution at 37 'C for one hour and were taken out of the solution. The bladders were
rinsed in saline and water to eliminate dye from the urothelium surface, and then the bladders
were inverted again so that the outer layer of the bladder could be checked for leaks. No dye
penetration through the knotted part of the bladder was observed by microscopic examination.
Figure 25. Procedure of inverting the rat bladder: (top) Sprague Dawley rat bladder, about 1 cm in length.
(Middle) Inverted bladder on a cotton tipped applicator. (Bottom) The inverted bladder knotted by suture.
Each inverted bladder was placed in each lidocaine solution (1 mL of lidocaine solution
in 7 mL vial) having different concentration and pH. Bladders were immersed completely in the
solution to make sure the whole inner bladder surface was in contact with the lidocaine solution.
Each vial was capped to avoid evaporation and placed in an incubator at 37 C. Incubation time
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was 10 min, 1 hour, 1 day, 3 days or 5 days, and the bladder was removed from the solution after
the designated incubation time. Each bladder, after taken from a vial, was rinsed three times in
phosphate buffered saline (PBS) to remove excess lidocaine solution surrounding the bladder.
Tweezers were also rinsed in PBS to avoid possible contamination. Each bladder was cut off
below the suture, and then it was weighed. Each prepared bladder sample weighed about 100 mg.
Lidocaine tissue concentration was detected by liquid scintillation counting (LSC)
method. The method of whole tissue solubilization was adopted for the extraction of lidocaine
from the bladder tissue, and the detailed procedures can be found in the reference. Weighed
tissue samples were placed in 20 mL glass scintillation vial. 1 mL of tissue solubilizer
(SolvableTM , PerkinElmer, Inc.) was added to the vial, and it was placed in an oven at 50-60 'C
for about 3 hours until tissue was completely dissolved. Once the vials had been removed from
the oven and the tissue had been dissolved, the amount of radioactivity in each vial was
quantified by liquid scintillation counter (Packard Tri-Carb 2200CA, PerkinElmer, Waltham,
MA). Raw data (disintegrations per minute, DPM) from the liquid scintillation counter were
converted to nanocuries (nCi) by using the conversion factor of 2,200 dpm = 1 nCi. 10 mL of
the LSC cocktail (Hionic-Fluor, PerkinElmer) was poured into each vial. The sample vials were
placed in rack inside the scintillation counter for at least an hour before counting for temperature
and light adaptation. The radioactivity in each sample was detected using the proper protocol for
14C in the scintillation counter, and the data was analyzed after running the tissue samples. The
total radioactivity counted in each vial was divided by the tissue mass to normalize the amount of
lidocaine absorbed in the bladder tissue.
Figure 26. The effect of pH on the absorption of lidocaine in rat bladder for 1 hour and 1 day. The bladder
samples were placed in 1% lidocaine solution (0.06 piCi/mL).
Figure 26 shows the effect of pH on the absorption of lidocaine into the bladder tissue.
The lidocaine concentration of the tested solutions was all 1% (10 mg/mL), and tested pH were
4.0, 5.0, 6.0, 6.85, 7.0, 8.0 and 8.5. The lidocaine absorption to the bladder is shown to be
slightly affected by the pH of lidocaine solution after an hour. There is, however, no significant
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effect of pH on lidocaine absorption after one day. The plateau tissue concentration (or absorbed
lidocaine mass per bladder tissue mass) is about 10000 mg/kg or 1%, which is the lidocaine
concentration of the vial where the bladder was immersed. This result implies that the topical
absorption of lidocaine from the bladder for a long term period can be independent of the pH of
the lidocaine solution. This result also indicates no need to buffer the lidocaine solution in situ in
the bladder for a long term application to increase the topical lidocaine absorption from
urothelium.
Figure 27 shows the effect of the concentration and pH of lidocaine solution on the
lidocaine absorption into the bladder tissue over the time (n=3 for each pH and each time point).
Error bars indicate the standard deviation for three samples. Lidocaine tissue concentration
increases quickly (within about ten minutes) and reach plateau for both 10-5% and 1% lidocaine
solutions. The plateau lidocaine tissue concentration for 10-5% lidocaine urine solution is in the
order of 0.1 mg/kg or 10-5% while that for 1% lidocaine urine solution is in the order of 10000
mg/kg or 1%. This result means that the partition coefficient for lidocaine tissue to lidocaine
solution is about unity for in vitro lidocaine absorption into urothelium. Higher lidocaine
concentration shows higher lidocaine absorption into urothelium. Future studies will include
obtaining tissue concentration-depth profiles for the in vivo setting using a cryomicrotome
technique at multiple time points to establish the in vivo lidocaine distribution model in the
bladder.
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Figure 27. Lidocaine tissue concentration-time profiles for 10-s% and 1% lidocaine solutions
pH and each time point. Error bars indicate the standard deviation of three samples).
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Chapter 5 In vivo lidocaine exposure studies in a rabbit model
In vivo drug exposure studies with intravesical lidocaine have been performed to
investigate the absorption of lidocaine by the bladder. Two types of in vivo experiments were
performed with a rabbit model. One was to instill lidocaine solution directly into the bladder and
the other was to implant the lidocaine delivery device into the bladder. The solution instillation
was performed to emulate conventional intravesical solution instillation treatments while the
device implantation was done to investigate treatment with the intravesical drug delivery device.
5.1 Intravesical instillation of lidocaine solution
Intravesical instillation of lidocaine solutions is used to
cystitis/painful bladder syndrome (IC/PBS) [14, 15, 52-56].
intravesical lidocaine therapy shows that pain experienced by
because the sensory neurons within the submucosal plexus are
related to the lidocaine concentration within the bladder wall.
lidocaine solution was conducted with a rabbit model, and tissue
lidocaine were measured.
treat patients with interstitial
A pharmacokinetic study of
IC/PBS patients is relieved
blocked [14]. Pain relief is
Intravesical instillation of a
and plasma concentrations of
The study was conducted with male New Zealand White rabbits weighing 2.5-2.9 kg
(Covance Inc.). The rabbits had no restrictions on food and water. The rabbits were cared for in
compliance with protocols approved by the Massachusetts Institute of Technology Committee on
Animal Care, in conformity with the NIH guidelines for the care and use of laboratory animals
(NIH publication #85-23, revised 1985). Intramuscular injection of ketamine (35 mg/kg) and
xylazine (5 mg/kg) was used to anesthetize the rabbits, and the rabbits were kept under
anesthesia during the experiment. Sterile ocular lubricant (Puralube Ointment, Fougera, Inc.
NY) was applied to relieve dryness of the eyes during anesthesia. The animals under adequate
depth of anesthesia were positioned supinely. Blood samples were drawn from the marginal ear
vein with a 24-gauge catheter. A 10-Fr pediatric Foley catheter (Rusch, Teleflex Medical, IL)
was inserted into the urethra, and 3 mL distilled water was used for ballooning within the bladder.
Lubricant (Surgilube, Fougera, Inc. NY) was applied on the surface of the catheter to facilitate
the insertion of the catheter through the urethra. The bladder was emptied by collecting urine
through the inserted catheter. 10 mL of lidocaine aqueous solution made with sterile water and
lidocaine hydrochloride was instilled by a syringe attached to the end of the Foley catheter. The
dose was 2 mg/kg or 5 mg/kg, which was based on the clinical studies [14, 15]. Blood samples
were collected before and after the intravesical instillation at multiple time points through the
catheter in the ear vein. The bladder was emptied after 1 hour or 2 hours, which is the solution
dwell time in the bladder. Then, the Foley catheter and the ear vein catheter were removed from
the rabbits. The rabbits were placed into the cage after recovering from the anesthesia. The
rabbits were taken out of the cage afterwards at about 10 hours and 24 hours for collecting blood
samples from the marginal ear vein using a 23-gauage butterfly needle (Surflo Winged Infusion
Set, Terumo Medical Corporation). Then, the animals were euthanized at 24 hours by
pentobarbital overdose and the bladders were extracted for the tissue collection. Methods to
detect lidocaine in blood and bladder tissue as well as sample preparation methods are described
in the section 5.3.
5.2 Implantation of intravesical drug delivery device
The study was conducted with male New Zealand White rabbits weighing 2.5-3.2 kg
(Covance Inc.). The rabbits had no restrictions on food and water. The rabbits were cared for in
compliance with protocols approved by the Massachusetts Institute of Technology Committee on
Animal Care, in conformity with the NIH guidelines for the care and use of laboratory animals
(NIH publication #85-23, revised 1985). A modified urethral catheter (10 Fr, feeding tube and
urethral catheter, Kendall, Sovereign, Tyco Healthcare) was made by cutting the rounded closed-
tip end of the catheter and flame polishing the cut surface to make it smooth. The device was
stretched and pushed gently into the smoothened end into the catheter until the device was fully
loaded into the catheter. Ethylene oxide (EtO) gas was used to sterilize the device-loaded
catheter as well as the push rod. Intramuscular injection of ketamine (35 mg/kg) and xylazine (5
mg/kg) was used to anesthetize the rabbits and they were kept under anesthesia during the
experiment. Sterile ocular lubricant (Puralube Ointment, Fougera, Inc. NY) was applied to
relieve dryness of the eyes during anesthesia. The animals under adequate depth of anesthesia
were positioned supinely, and the catheter loaded with the device was inserted into the bladder
through the urethra of the animal. Lubricant (Surgilube, Fougera, Inc. NY) was applied on the
surface of the catheter to facilitate the insertion of the catheter through the urethra. The tip of the
push rod was also lubricated to reduce the surface friction between the inner surface of the
catheter and the push rod. Urine could be collected at this point through the inserted catheter
once the catheter tip was placed in the bladder. Abdominal pressure was applied to stimulate
voiding of the urine from the bladder. The device was deployed from the catheter into the
bladder by the push rod. The catheter was pulled out after the device implantation. The
sequence of the device implantation is shown in Figure 28. The entire procedure was performed
aseptically. An x-ray was taken to confirm the implantation location. Blood samples were
collected from the marginal ear vein or artery of the animals at multiple time points before and
after the device implantation. The marginal ear vein is normally used for smaller volume of
blood samples while artery is for larger volume samples. Several techniques were employed to
allow for serial blood sampling. Hematoma and bruising were minimized, especially when
blood was drawn from the ear artery. Blood sampling was also performed distally to proximally
along the blood vessel (from the tip of the ear and toward the base of the ear), alternating ears
instead of using the same vein consecutively. The animals were secured in a restrainer to avoid
inadvertent movement during blood sampling.
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Figure 28. The device implantation sequence by the catheter-stylet system
X-ray images were taken at multiple time points (immediately after implantation, 2 days
after, and 9 days after device implantation) with one rabbit (Figure 29). X-rays were taken both
.. .... 
...........
in the right lateral recumbent position and supine position. Multiple x-ray images taken at
different times revealed that the device can move freely within the bladder rather than staying in
one position. The platinum parts embedded at the end of the two arms are shown more clearly
due to its enhanced radioopacity compared with nitinol. The device was well tolerated by rabbits
during the period of in vivo study without any health problem. The animals were euthanized at
multiple pre-determined end points by pentobarbital overdose and the bladders were extracted
for the tissue collection.
Figure 29. Radiographs of implanted devices. (Top row) Immediately after implantation, (Middle row) 2
days after implantation, (Bottom row) 9 days after implantation. Left column is when the animal was in the
right lateral recumbent position and right column is when the animal was in the supine position.
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5.3 Measurement of the lidocaine concentration in blood and bladder
5.3.1 Blood samples
Blood samples from the animals were collected from marginal ear vein or artery in blood
collection tubes (BD Vacutainer, Lithium Heparin #367884, Becton, Dickinson and Company).
Collected blood sample was centrifuged at 10000 RPM for 10 minutes at room temperature
(Centrifuge 5415C, Eppendorf) and supernatant or plasma, was used in an Enzyme-Linked
ImmunoSorbent Assay (ELISA). Lidocaine ELISA kits (#106719-1, Neogen Corporation, KY)
were used as suggested by the manufacturer to detect lidocaine in plasma. The ELISA kit
operates based on competitive binding between the lidocaine or its metabolite in the sample and
the lidocaine-enzyme conjugate to a limited number of antibody binding sites (anti-lidocaine
antibodies). The lidocaine hapten and horseradish peroxidase (HRP) were linked to form a
covalently-linked lidocaine-enzyme conjugate [57-59]. The optical densities of each sample
were measured using a micro-plate reader (SpectraMax plus384, Molecular Devices) at a
wavelength of 650 nm. Standard dilutions of plasma for a standard curve were prepared by
centrifugation of blood spiked with lidocaine. The concentrations for standard dilutions were 0,
0.5, 1, 2, 4, and 8 ng/mL. Representative typical standard curves are shown in Figure 30.
Dilutions of 1/10, 1/100, and 1/1000 were performed to bring sample concentration within the
assay range. Dilutions of samples were performed with phosphate buffered saline solution with
bovine serum and a preservative (EIA buffer, Neogen Corporation, KY).
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Figure 30. Representative typical standard curve for standard dilutions of plasma (0, 0.5, 1, 2, 4, and 8
ng/mL). Cubic spline curve (top) and semi-log graph (bottom).
5.3.2 Bladder tissue samples
Bladders were collected from the animals after multiple time points, 1, 2, 3, and 6 days.
The bladder from each animal was cut into 100-200 mg segments after removing as much fat and
connective tissue from the bladder as possible. Each piece of bladder tissue segment was
weighed, and a tissue homogenization process was followed. The bead beater (Mini-Beadbeater-
1, BioSpec Products, OK) was used to homogenize the tissue. The bead beater vigorously
agitates a sealed vial containing tissue, extraction solution and hundreds of minute beads. A
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weighed tissue segment was placed into a 2 mL conical bottom vial with o-ring seal cap
(BioSpec Products, OK) containing zirconia beads with 1 mm diameter (BioSpec Products, OK)
and 1 mL of EIA buffer (Neogen Corporation, KY). Heating of the homogenate during bead
beating was minimized by starting with pre-chilled vials in ice water as well as by alternating
one minute bead beating and one minute cooling (cooling between bead beating). Bead beating
was repeated several times until the beads and tissue flowed freely inside the vials. The number
of bead beating depends on the mass of tissue segment; as a larger tissue mass requires more
bead beating. The homogenate after the completion of homogenization process was transferred
to a 1.5 mL microcentrifuge vial after the beads settled to the bottom of the 2 mL conical bottom
vial. Then, the homogenate was centrifuged at 10000 RPM for 10 minutes at room temperature
(Centrifuge 5415C, Eppendorf), and the lidocaine concentration in the supernatant was
quantified by ELISA as described above. Standard dilutions for a standard curve were made
using a control rabbit bladder (Pel-Freez Biologicals). The rabbit bladder was cut into 100-200
mg sections, and known amounts of lidocaine was spiked into the vial containing the beads and
EIA buffer. The homogenization process for standard dilutions was the same as that of tissue
samples. The concentrations for standard dilutions were 0, 0.5, 1, 2, 4, and 8 ng/mL. Sample
dilutions of 1/10, 1/100, and 1/1000 were performed with EIA buffer (Neogen Corporation, KY)
to bring sample concentration within the assay range.
5.4 Biodistribution of lidocaine
Lidocaine concentration in plasma and bladder tissue after either intravesical instillation
treatment or device treatment was measured to investigate the biodistribution after each
treatment. Lidocaine plasma concentrations over time for the instillation treatment (dotted lines)
and the device treatment (solid lines) are shown in Figure 31. The weight of each animal is also
shown (Figure 31, inset). The device containing 2 mg is denoted as '3 day device' while the one
with 4 mg as '6 day device'. Specifications and in vitro release curves for 3 day and 6 day
devices are shown in Chapter 2.
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Figure 31. In vivo results for lidocaine plasma concentration. Lidocaine plasma concentration for the
instillation treatment (dotted lines) and the device treatment (solid lines). Errors bars represent the standard
deviation for the duplicate samples for ELISA assay.
Intravesical instillation of lidocaine solution resulted in an initial surge in the plasma after,
but lidocaine was not detected in plasma after 24 hours. The plasma concentration for the
instillation treatment is characterized by the sudden increase and then rapid drop of lidocaine
plasma concentration. The peak plasma concentration from the instillation of lidocaine solution
. .........-
with the dose of 5 mg/kg and two hour retention time exceeds 100 ng/mL, which is within a
factor of ten of the known toxicity limit of lidocaine [11, 21-24]. The high initial peak
concentration may, however, be necessary to extend the relief between repeated instillations in
the intravesical solution therapy approach. Figure 31 was redrawn in Figure 32 with modified
vertical scale in order to show the results of the device treatment.
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Figure 32. In vivo results for lidocaine plasma concentration. The scale of the vertical is modified from Error!
Reference source not found. to better show the results from the device treatment. Errors bars represent the
standard deviation for the duplicate samples for ELISA assay.
The device treatment shows much lower but extended plasma lidocaine level than that of
the instillation treatment. The in vitro release experiments with 3 day device in Chapter 2
showed that the drug release rate from the device slows down after 12 hours, and this fact is
reflected in the in vivo exposure result. The pilot in vivo exposure study with 6 day device is also
shown in Figure 32 labeled with the number 14. Compared with the 3 day device, the 6 day
device has a doubled payload as well as a more extended release profile. There was an initial lag
time observed for the in vitro release profile for the 6 day device (Figure 14, device 'IV'). The
thicker wall of the silicone tube for the 6 day device is hydrated during the initial lag time before
lidocaine starts to release from the device. The in vitro time lag was reflected in the in vivo
exposure result in Figure 32. The depot delivery method by the device may avoid the high peak
plasma concentration yet provide higher drug exposure for a long-term application.
The bladder tissue concentration of lidocaine is a more direct index to determine the
efficacy of treatment than the plasma concentration since the target site for the intravesical
treatment is the bladder tissue. Figure 33 shows the lidocaine concentration in the bladder tissue
over time. The animals implanted with the 3 day device were sacrificed for bladder extraction at
one, two, and three days after device implantation. The tissue concentration decreases over time.
The tissue concentration from the 6 day device shows that the lidocaine level at day 6 is
comparable to the level after 24 hours for the 3 day device. The tissue concentrations at 24 hours
after intravesical instillation of lidocaine solutions were also measured by the same method, but
lidocaine was not detected or below the detection limit (about 0.5 ng/mL) of the current lidocaine
ELISA kit. It should be noted that the lidocaine tissue concentration is in the order of microgram
per gram of tissue. Tissue homogenate samples were diluted by 1:1000 to bring sample
concentration within the ELISA assay range. The rabbits, unlike humans, were under general
anesthesia for cystoscopic implantation of the device. The reduced fluid intake of individual
animal while recovering from anesthesia affects the drug release from the device, which is
related to the drug plasma level as well as drug tissue level. Some clinical treatments
recommend fluid restriction after intravesical instillation to achieve the highest exposure possible
and reduce wash-out, but this would ideally not be necessary.
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Figure 33. Lidocaine tissue concentration (jag/g). Device residence time and drug payload are indicated.
Errors bars represent the standard deviation for the samples from multiple animals or from multiple
positions in the bladder.
Lidocaine plasma and tissue concentration for each animal are simultaneously shown in
Figure 34 to represent the correlation between them. The in vivo results at 24 hours after the
intravesical instillation treatment are also shown in Figure 34, but they are all negligible
compared with the results from the device treatment. Horizontal error bars indicates the standard
deviation for the tissue samples from multiple positions in the bladder, and vertical error bars
indicate the standard deviation for the duplicate plasma samples for the assay. There is a general
trend that higher plasma concentrations are associated with higher tissue concentrations. The
tissue concentration is approximately thousand times as high as that for the plasma concentration.
tissue concentration is approximately thousand times as high as that for the plasma concentration.
- I I-
Therefore, our depot delivery approach by the device treatment may provide higher drug
exposure to the bladder tissue while avoiding the high peak plasma concentration.
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Figure 34. Correlation between lidocaine plasma concentration and tissue concentration. Errors bars
represent the standard deviation for the tissue samples from multiple positions in the bladder or for the
duplicate plasma samples for ELISA.
Lidocaine urine concentration was also measured for two animals that were treated with
the 3 day device and 6 day device individually. Lidocaine ELISA kits (#106719-1, Neogen
Corporation, KY) were used to detect lidocaine in urine. Rabbit urine was collected from the
bladder after the animal was sacrificed. Collected urine sample was centrifuged at 10000 RPM
for 10 minutes at room temperature (Centrifuge 5415C, Eppendorf), and then the supernatantthe 3 a eiead6dydvc niiuly ioan LS is(161-,Noe
CoprtoK) eeue odeetldcie nuie abi rn a oletdfoEh
--- I
was used for the assay. Standard dilutions of urine for a standard curve were made with artificial
urine (Surine Negative, Dyna-Tek Industries, Inc.) spiked with lidocaine. The concentrations for
standard dilutions were 0, 0.5, 1, 2, 4, and 8 ng/mL. Dilutions of 1:10, 1:100, and 1:1000 were
performed to bring sample concentration within the assay range. Lidocaine urine and tissue
concentration are shown in Figure 35. The bladder tissue and urine samples were collected from
each animal after 3 days with the 3 day device (Figure 35, left) or after 6 days with the 6 day
device (Figure 35, right). The order of magnitude of urine concentration is comparable to that of
tissue concentration, which was previously shown in Figure 27 for in vitro lidocaine absorption
studies with lidocaine urine solutions of 10-5% (0.1 [pg/mL) and 1% (0.01 g/mL).
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Figure 35. Lidocaine concentration of tissue and urine. Device implantation time and drug loading are
indicated. Errors bars represent the standard deviation for the tissue samples from multiple positions in the
bladder or for the duplicate plasma samples for ELISA.
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5.5 Implantation in the seminal vesicle
A pilot in vivo experiment was conducted to explore the situation when the device is
implanted in a location other than the bladder, such as the seminal vesicle for men. Figure 36
shows the genital organs of a male New Zealand White rabbit, and the seminal vesicle is located
at the position from 2.5 cm to 3.5 cm in Figure 36. The seminal vesicle has sac-like structure
originating from the base of the bladder [60, 61]. Figure 37 shows porcine genitourinary organs,
which is similar to those of a rabbit. The device made of silicone tube and monofilament nylon
suture (Ethilon, monofilament nylon, size 1, 4.0 metric, Ethicon, inc.) was implanted to the
lumen of the seminal vesicle of a rabbit. The drug release unit in the device was the same as that
for the 3 day device, and the drug load was 2 mg as in the 3 day device. Lidocaine plasma
concentration over the time is shown in Figure 38. The peak concentration appeared at 48 hours
after device implantation, which is delayed compared with the result of the previous experiment
for the 3 day device in the bladder. The water-scarce environment in the seminal vesicle
compared with the bladder may have caused the longer induction time when water permeates
through the silicone device and dissolve the solid cast lidocaine in the drug reservoir to initiate
drug release.
Figure 36. Genital organs of a male New Zealand White rabbit. The bladder is shown in the left and the
penile urethra in the right.
Vesicular gland
Prostate B rthral gland
Daluhi
Epididymis
Figure 37. Porcine male reproductive system (Diagram reproduced here with permission from Dr.
Charlotte L. Ownby, College of Veterinary Medicine, OKlahoma State University, Stillwater, OK)
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5.6 Encrustation and low calcium diet
Rabbits are unusual in that the plasma calcium concentration reflects the dietary calcium
level. Figure 39 shows that the plasma calcium concentration increases in proportion to the
dietary calcium level [62, 63]. Rabbits lack the homeostatic control of their serum calcium level
while many other animal species homeostatically maintain the serum calcium level at a nearly
constant level by the interactions the parathyroid hormone (PTH), vitamin D, and calcitonin [62,
64]. Another unusual concept of calcium metabolism in rabbits is that the urine is the main route
of excretion of excess calcium while the bile is the major route of calcium excretion in other
animals [65-68]. Rabbits excrete about 45-60% of their ingested calcium in the urine while other
mammals excrete only less than 2% of ingested calcium in their urine [62, 63]. Rabbit urine
appears cloudy, creamy, or turbid in general. Figure 40 shows rabbit urine in a tube placed
vertically so that excess calcium carbonate crystals settled to the bottom of the tube.
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Figure 38. Lidocaine plasma concentration with the device implanted in the seminal vesicle. The device
shape was that of the one at top right in Figure 7.
Cofisidering the excessive calcium present in the rabbit urine, it is not surprising that
encrustation can be found on devices even after a short dwelling time in the bladder. Studies on
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Figure 39. The effect of the dietary calcium level on the plasma calcium level. The range for calcium
excretion for the rabbit is about 45-60% while other mammals excrete less than 2% of ingested calcium in
the urine [63].
Urine was placed vertically, not centrifuged, andFigure 40. Rabbit urine in 15 mL centrifuge tube.
precipitated calcium carbonate is shown as sediment.
the encrustation on urinary tract biomaterials suggested that formation of encrustation depends
on catheter materials and the urine composition [69-73]. The placebo device without drug
reservoir was implanted to the bladder and retrieved at nine weeks after implantation. The outer
surface of the device was silicone. The long-term device toleration study with a rabbit clearly
shows the severe encrustation on the device in Figure 41. Encrustation could be observed in x-
ray radiographs before retrieval of the device from the bladder. More encrustation was observed
on both arms at the device compared to other locations of the device. This may reflect the fact
that once implanted, each arm has less chance of being directly in contact with the bladder wall
and experiences less deformation during the residence of the device in the bladder compared to
other locations of the device.
(a) (b)
I'1 cm
(C) (d)
Figure 41. Encrusted placebo device without drug release reservoir. The device was implanted in the
bladder for 9 weeks. Radiographs (a) in the supine position and (b) in the right lateral recumbent position.
(c) The device before implantation. (d) The retrieved device from the bladder at 9 weeks after implantation.
The calcium encrustation on the device can be seen in Radiographs.
Encrustation on the device can be reduced by surface treatment such as coating with
heparin, pentosanpolysulfate (PPS, a semisynthetic polysaccharide chemically similar to heparin),
or oxalate-degrading enzymes from Oxalobacter formigenes [73-76]. Surface treatment with
heparin-like polysaccharides for our silicone device should be investigated further. Another
method to reduce encrustation for the rabbit model is to adopt a low calcium diet since the urine
calcium excretion is in proportional to the dietary calcium intake for rabbits as described earlier.
A rabbit's blood and urine calcium concentrations directly reflect dietary calcium intake.
................................................................
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Reduced calcium in rabbit diet leads to lowered serum calcium levels, and subsequently the
amount of calcium excreted in the urine will decrease. The chemical composition for control
rabbit diet (Laboratory Rabbit Diet HF, 5326, PMI Nutrition International) is shown in Appendix
2, where the calcium is 0.95% and phosphorus is 0.51%. Customized low calcium diet
(Modified Labdiet 5321 w/ reduced calcium, 5S4T, PMI Nutrition International) was formulated
by TestDiet , and the chemical composition is shown in Appendix 3, where the calcium is
0.51% and phosphorus is 0.44%. Each composition was carefully controlled to provide the
animals with necessary nutritional ingredients. The low calcium diet contains 46% less calcium
than the control diet. Each diet has a pellet form with similar size of about 4-5 mm diameter and
10 mm height (Figure 42).
Figure 42. Rabbit diet pellets. (Left) control rabbit diet (LabDiet®). (Right) low calcium diet (TestDiet®).
Control diet and low calcium diet were used to feed the rabbits during in vivo
experiments with the device. Rabbits were fed with the control diet more than two weeks before
starting the low calcium diet. Rabbits did not show any reluctance to the low calcium diet.
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There were two different feed durations for the low calcium diet, which were two and four weeks.
Figure 43 shows the devices from three rabbits after three days. Rabbits were fed with the
control diet, the low calcium diet for two weeks, or the low calcium diet for four weeks before
and during the device implantation. The device from the rabbit with the control diet was fully
covered with calcium encrustation. The encrustation on the device from the rabbits with the low
calcium diet was less than the one from the control diet rabbit. There appears to be an optimum
duration for the low calcium diet as the 4 week low calcium diet device exhibited more
encrustation than the 2 week low calcium diet device, but still less than the control diet. These
results illustrate the utility of the low calcium diet for the rabbit model to reduce the encrustation
on the device implanted in the bladder. The device with anti-encrustation coating using heparin-
like polysaccharides combined with a low calcium diet will increase the utility of a rabbit model
for the long-term study of the intravesical drug delivery device.
Figure 43. The device with encrustation after 3 day implantation in the rabbit bladder: (left) the device from the
rabbit with the control diet, (middle) the device from the rabbit with low calcium diet for 2 weeks, (right) the
device from the rabbit with low calcium diet for 4 weeks.
....................................................
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5.7 Lidocaine toxicity
Adverse toxic reactions should be considered when lidocaine is used as a local anesthetic
agent although the frequency of toxic reactions is extremely low [77]. Systemic toxicity
involves the central nervous system (CNS) and cardiovascular system, and local toxicity includes
localized nerve damage and localized neural and skeletal muscle irritation. Figure 44 shows the
signs and symptoms of systemic toxicity with respect to lidocaine plasma concentration. High
lidocaine plasma concentration should be avoided to prevent possible systemic toxicity when
lidocaine is used as a local anesthetic agent. In vivo exposure studies with the intravesical device
showed that low lidocaine level in plasma can be achieved while maintaining lidocaine level in
bladder tissue a thousand-fold high in the section 5.4. Therefore, there is low risk of systemic
toxicity with the device treatment. Studies on local toxicity using an isolated rabbit vagus nerve
and intact rabbit sciatic nerve reported that there were no signs of neurotoxicity with lidocaine
[78, 79]. Studies on the long-term application of lidocaine patch suggests that extended
application of the patch does not cause sensory loss at the application site [80-83]. No signs of
systemic or local toxicity were observed in the studies conducted.
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Figure 44. Relationship of signs and symptoms of local anesthetic-induced central nervous system (CNS)
toxicity to plasma concentrations of lidocaine [77].
Chapter 6 Design scheme for tubular drug release device
6.1 Basic equations for tubular osmotic pump
The drug delivery device has a tubular osmotic pump made of silicone. Other
biocompatible polymer tubes such as polyurethane can be used depending on its permeability to
water (and drug) and mechanical properties. Design equations for the tubular osmotic pump are
important to obtain the desired drug payload and release rate. Tube thickness is related to
mechanical integrity and water permeability. Tube inner diameter and tube wall thickness
determine the drug payload and outer diameter of the tube. Tube length affects both drug
payload as well as the macro size or loop diameter of the tubular osmotic pump. Osmotic
surface area where water can permeate through the tube is affected by tube outer diameter and
tube length. All these parameters influences the overall performance of the osmotic pump
depends on them.
The inner side of the tube contains drug and the drug contained tubular osmotic pump is
our system of consideration for drug mass transfer to the outside medium. Each parameter is
defined below.
C: instantaneous drug concentration in the device reservoir
p: drug density
S: drug solubility
d: tube inner diameter
h: tube wall thickness
D: diameter of macro loop made of tube
L: tube total length, L=tD
Ln: tube length without permeation blocking sheath
Ls: tube length with permeation blocking sheath, Ls=L-Ln
yrd 2 L
V: volume of drug reservoir, V =
4
m: instantaneous drug amount remaining in the device reservoir, m = CV = C L4
m,: total drug payload, mp = pV = p d L4
AH: osmotic pressure difference between the inside and outside of the tube
AHs: osmotic pressure difference at saturation between the inside and outside of the tube
k: permeability coefficient for solvent transport
A: osmotic surface area for water permeation, A=n(d+h)Ln
tz : duration of zero order release
dm dm AH
: the rate of drug mass change in the reservoir, = -kA C
dt dt h
dm A-shz,: zero order release rate, hz = - = kA sdt zero h
m,: amount released during zero order release, mz = nz -tz
The notation of 'dm/dt' is defined differently from the definition in section 2.4. Here, it is
defined as the rate of drug mass loss in the device reservoir since 'm' indicates the instantaneous
drug amount remaining in the device reservoir. The minus sign in the expression 'dm/dt' reflects
the fact that the device will lose its drug by osmotic release once the device is immersed in water
or urine. When the osmotic pressure of the surrounding medium is small enough compared to
the osmotic pressure of the formulation inside the drug reservoir, van't Hoff s law can be used to
obtain:
=A C (6.1)
Awhere the proportional relationship between thes S
where the proportional relationship between the osmotic pressure and concentration is used.
The drug release rate from the device remains constant at the initial time period when the
concentration inside the drug reservoir is the solubility of drug loaded.
released during this initial 'zero-order release period' can be expressed as
m. =( 1
The amount of drug
S)m P
P)
(6.2)
The drug release rate decreases after the zero-order release period as the drug concentration
inside the reservoir becomes reduced. The rate of drug mass change (dm/dt) in the reservoir can
still be expressed in terms of zero order release rate ( r z ):
dm Ah i kA s S)C AIH
dt h h SA s
(6.3)
The expressions for the amount of drug remaining in the reservoir (m) and the rate of drug mass
change (dm/dt) are different for two time periods, the zero order release period and the non-zero
order release period. The expressions for the zero-order release period (0 t I t,) are:
m = mP -m t (6.4)
(6.5)dm = -
Integrating Eq. (6.3) is used to find the expressions for the non-zero order release period (t > tz ).
Drug concentration (C) and drug mass (m) are time-dependent variables and are related by
(6.6)m =CV
Integrating Eq. (6.3) from tzto t after combining Eq. (6.6) with Eq. (6.3), we get
m-2dm = _ mztdm (SV)2dt
Drug mass remaining inside the reservoir at time t (> tz ) can be expressed as
S
m = -m
p
1+ P (t -tz)
and
dm
dt
-m z [1
- 2
+ P (t-tz)
S mp
where
t = I S m p-
'z = .-
The drug mass in the device reservoir beyond tz can be expressed as
m = amp (a < 1) (6.11)
where a is the ratio parameter indicating remaining drug mass compared to the initial loading
(for example, if a is 0.05, then 5% of the total payload remains in the device or 95% of the total
loading is released out). Substituting Eq. (6.11) into Eq. (6.8) gives the time t as
m S
t=tz + +
S 1 S22-+ 2
p ap2
m
where t, is replaced by Eq. (6.10). We can see from Eq. (6.12) that - is the factor determining
the delivery time scale. This result implies that total payload and initial zero order release rate
decides the overall behavior of drug release profile over time.
(6.7)
(6.8)
(6.9)
(6.10)
(6.12)S1 S 2 m,
-- = 1-ap2 mh
Examples of the application of Eq. (6.12) are presented here. Figure 45 shows in vitro
lidocaine release profiles using three different devices made of silicone. Drug payload (m,) and
zero-order drug release rate (rhz) are different for each device. The relative values of two
variables are shown in Table 4 with respect to the values for the device 'A'. The device 'A' has
a length of 2 cm and the device 'B' has half the length of the device 'A'. Therefore, both drug
payload and zero order release rate for device 'B' are half the values of the device 'A'. This
results in the same delivery time scale for 'A' and 'B'. We can see from Figure 45 that overall in
vitro release profiles with respect to time are similar for 'A' and 'B'. The device 'C' has the
same length as the device 'A'. Half the length of the device 'C' is, however, covered with
polyurethane sheath to minimize the water permeation so that the zero order release rate for 'C'
can be half the value for 'A'. Therefore, the delivery time scale of 'C' is as twice as that of 'A'.
Figure 45 shows that the drug release for the device 'C' is twice as slow as that for 'A'.
Table 4. Three different types of device
Variable Drug payload Zero order release rate Delivery time scale
Device (m,) (ritz) (m, / rhz)
A 1 1 1
B 1/2 1/2 1
C 1 1/2 2
2000
CC
E
E
-*-A) 2 mg load, 2 cm (n-3)
500
-- B) I mg load, 1 cm (n=3)
- C) 2 mg load, 2 cm (half covered with sheath) (n=3)
0 24 48 72 96 120 144 168
Time (hrs)
Figure 45. In vitro release of lidocaine HCI in water at 37 °C
6.2 Design of tubular osmotic pump
Modification of design parameters is required to obtain a desirable drug delivery rate and
payload. In vitro release data for one device can be used to find design parameters necessary to
achieve a given drug delivery rate and payload. This section will describe the design method by
presenting several examples. In vitro release data is compared to in vivo exposure data for the
device 'A' in Figure 32, and the design parameters for this device will be referred to as the 'base
condition' in this section. The parameters for the base condition are specified as:
Base condition
- Tube inner diameter: do=0.3048 mm
~~~~ " " " "" ".............;
- Tube wall thickness: ho=0.1651 mm
- Tube length: Lo=2 cm
- Payload: mp,o=2 mg
- Treatment duration: about 3 days
Starting from the information on the base condition, our goal is to obtain design parameters or
dimensional information for the device with the desired delivery rate and payload. Two
variables, 'a' and 'b,' are defined as the multiplication factor for the target zero order delivery
rate and that for the target payload, respectively. The definitions yield the desired target
condition as follows:
Target condition
- Zero order delivery rate ( rh): 'a' times increase compared with the base condition
- Drug payload (mp): 'b' times increase compared with the base condition
It is assumed here that drug and tube material remain the same for both the base condition and
the target condition. The parameters for the target condition have no subscripts here. The zero-
order delivery rate condition gives
d+h L=d Lo+hho (6.13)
and the drug payload condition gives
d 2L = (do2Lo)b (6.14)
Tube wall thickness can vary, but here it is fixed for simplicity:
h = ho  (6.15)
A thin tube wall will deteriorate the mechanical integrity of the polymer tube while a thick tube
wall may cause undesirable longer induction time for initial drug release from the device. The
reasonable range of the tube wall thickness is determined by mechanical properties and water
permeation property of the polymer tube material.
6.2.1 Device made of polymer tube
A silicone tube with a thin wall can act as a water permeable membrane when drug is
loaded inside the tube. The case where the device consists of water permeable tube without a
polymer sheath will be considered. Silicone tube or other polymer tube can have sheath or
coating that is made of polymers with very low permeability to water to minimize water
permeation. This case will be treated in the section 6.2.2. The device 'A' and 'B' in Figure 45
show such a case. Water can permeate into the drug reservoir through the entire length of the
tube, and so
L= L, (6.16)
Quadratic equation for the inner diameter can be obtained from Eq. (6.13) and Eq. (6.14) as
d 2 (b / a)d (b / a)d2  (6.17)
d + ho do o ho =0 (6.17)
where one solution is positive and the other is negative. The positive solution is designated as
d,, and we get the solution for the tube length as
do Lb do + hO
L, - +h Loa (6.18)dl d, +ho
Two examples are shown below. We can obtain the tube inner diameter and tube length once the
multiplication factors for the delivery rate and the drug payload are chosen. Introduction of a
different polymer tube or drug into the drug delivery device will require another in vitro release
study to obtain the base condition for that specific combination of polymer and drug.
Table 5. Specifications for two examples of devices for human application
Multiplication factor For delivery rate (a): 10 For delivery rate (a): 20
For payload (b): 50 For payload (b): 200
Design parameter
Tube inner diameter (d,) 1.1326 mm 2.1303 mm
Tube length (L,) 7.2418 cm 8.1885 cm
Macro loop diameter (D) 2.3051 cm 2.6065 cm
Drug payload (mp) 100 mg 400 mg
Treatment period 15 days 30 days
6.2.2 Device with sheath for minimizing water permeation
A sheath made of polyurethane can be used to cover some portion of the tube in order to
minimize the water permeation through the polymer tube wall as in Figure 45. Special coating
such as parylene can also be used to reduce water permeation. The length covered with sheath is
denoted as Ls . The previous section corresponds to the case where Ls = 0 . This situation is
often met since diameter of working channel in cystoscope is usually less than 2.4 mm. Eq.
(6.13) and Eq. (6.14) show that the tube length (L) increases faster than the sheath covered
length (L,) as the tube inner diameter (d) deceases (L oc 1/ d 2 and L, oc 1/(d + h)). The length
of the portion covered with sheath is
Ls =L-L, (6.19)
Using Eq. (6.13), (6.14), and (6.19), the length covered with sheath is expressed as
Ls = D - (d° +k)La (6.20)
do, (Lob) / D)+ho
or using Eq. (6.18), we get
L D d, +h (6.21)
L1  D, d+ho
where subscript 1 indicates the case of no sheath used. The portion of the tube length covered
with sheath can be expressed in terms of the tube inner diameter (d) as
L a(d +h) d2  (6.22)s = d2  .
L bd2  d+h
or in terms of the loop diameter (D) as
Ls (do +ho)LoaL 1- (d° )La (6.23)L do +bLoD+7 h D
Two examples in the previous section are reconsidered here. The maximum value for the
macro loop diameter under consideration is limited to 5 cm. The adult human bladder capacity is
about 500 cm 3, and the corresponding diameter with the assumption of sphere shape bladder is
about 10 cm (V = zD 3 / 6). The device with a loop diameter of 5 cm will be only half the size
of the maximum linear length in the bladder, approximately. The multiplication factors for the
delivery rate (a) and the payload (b), respectively, are shown in Figure 46 and Figure 47. They
show the dependency of required sheath length (Ls) and sheath covered portion (Ls / L) on loop
diameter (D) and tube inner diameter (d) to achieve given delivery rate and payload. The
circle in each plot shows the case without sheath and the corresponding values are in Table 5.
Square indicates the case where the loop diameter is 5 cm in each plot. The payload for each
example is 100 mg and 400 mg, respectively. The sheath covered portion is less than 40% for
both cases. The tube inner diameter range for 100 mg payload case is smaller than that for 400
mg payload case.
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Conclusions and future work
7.1 Summary
This thesis covers the design and testing of a drug delivery device that is non-surgically
implantable in the bladder. A device with a retentive feature resistant to the contraction of the
bladder was implemented and tested in vitro and in vivo with a rabbit model. Analysis on
deformation of elastic ring and semi-circle was performed to find design parameters affecting the
elastic property of the device and to enable the fabrication of the device with low modulus
elastomers. A cylindrical solid form of chondroitin sulfate C (CSC) and lidocaine with a
diameter of approximately 300 tm was formulated to maximize the payload. In vitro drug
release experiments with CSC and lidocaine were performed to establish design equations for
modulating an osmotic drug release rate by changing device parameters such as the dimension
and permeability of semi-permeable membrane. Intravesical drug absorption models were
investigated to understand the role of the urothelium as a drug diffusion barrier and its effect on
the overall drug absorption into the bladder. An in vitro lidocaine absorption study with rat
bladders showed that the effect of pH on the lidocaine absorption into the urothelium is
insignificant after one day. In vivo tests using lidocaine, a local anesthetic used for IC/PBS
treatment, showed that a sustained and local treatment to the bladder can be achieved with the
device. The lidocaine bladder tissue concentration was found to be a thousand-fold higher than
the lidocaine plasma concentration at three and six days in a rabbit model. The combination of
low systemic and high local tissue concentrations with the device is ideal for intravesical
treatments with therapeutic agents such as lidocaine for IC/PBS, oxybutynin for OAB, and
chemotherapeutic agents for superficial bladder cancer. Finally, the design strategy for a
sustained two to four week intravesical drug delivery device for humans was suggested.
Chapter 7
7.2 Future directions
Future studies should investigate the intravesical drug delivery device for long-term
applications and additional therapeutic agents. Other animal models may avoid the calcification
problem observed with a rabbit model. Possible species (with available Foley catheter size)
include a dog (6-12 Fr)[84], a cat (3.5-5 Fr)[84], a pig (8-10 Fr)[85], and a sheep (8-14 Fr)[86]
compared with a rabbit (8-12 Fr)[87]. A device for long-term applications may require a larger
payload of drug, which necessitates a larger size catheter for device implantation. Histological
examination with a device for long-term use can be performed to investigate the safety and
tolerability of the device. An intravesical device made of biodegradable materials can be
pursued to remove the need for a retrieval procedure. Future studies may use the device for other
therapeutic agents that are currently used intravesically. Some exemplary drugs include
oxybutynin for OAB and mitomycin C and thiotepa for intravesical chemotherapy to reduce the
rate of bladder tumor recurrence.
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Appendix
Appendix 1. MATLAB code for the deformation of elastic circular ring
% R. Frisch-Fay, The deformation of elastic circular rings. Australian J of
Applied Science, 11, 1960, pp. 329-340.
close all
clear all
%F(phi,m) = int(l/sqrt(l-m*sin(t)^2), t=0..phi);
%E(phi,m) = int(sqrt(l-m*sin(t)^2), t=0..phi);
%[K complete,E_complete] = ellipticl2(pi/2, p.^2);
%[F,E] = ellipticl2(angle, p.^2);
%1) Nodal Elastica
% 0 < P < 0.3148EI/rA2
clear all
SIZE=5000;
i=0;
m=linspace(10A-10,1,SIZE);
[F,E] = ellipticl2(pi/4, m);
p=m.A(1/2);
NFl=(8/piA2)*m.*F.A2;
ND1=-sqrt(2*NF1.A^-1) .*(2*E.*p.^(-1)-F.*(2*p.A-1-p));
for i=2:SIZE-1
slopeyl(i)=(NFl(i+l)-NFl(i))/ (ND (i+l)-ND1(i));
slopexl(i)=(NDl(i+l)+ND1(i )/2;
end
NFl(1)=0;
ND1(1)=0;
%if p=l, ND1=0.0504 and NFl=0.6297
% 2) Oval shape
% 0.3148EI/rA2 < P < 1.3932EI/r^2
p=linspace(1/sqrt(2),1,SIZE);
Ob=(asin( (p.^-1)* (1/sqrt(2) ));
[F,E] = ellipticl2(Ob, p.^2);
NF2=8/piA2*F. A2;
ND2=1-sqrt(2*NF2.A-1).*(2*E-F);
for i=l:SIZE-1
slopey2(i)=(NF2(i+l)-NF2(i)) / (ND2(i+) -ND2(i));
slopex2(i)=(ND2(i+1)+ND2(i))/2;
end
plot(slopex2,slopey2)
%if p=l/sqrt(2), ND2=0.2822, and NF2=2.7864
% 3) Peanut shape
% 1.39EI/r^2 < P
SIZE=5000;
p=linspace(l/sqrt(2),1,SIZE);
Ob=(asin( (p.^-l)*(1/sqrt(2) ));
[F,E] = ellipticl2(Ob, p.^2);
[Kc3,Ec3] = ellipticl2(pi/2, p.^2);
NF3=8/piA2*(2*Kc3-F) .2;
ND3=1-sqrt(2*NF3.A-1).*(4*Ec3-2*Kc3-2*E+F);
for i=l:SIZE
if ND3(i)>l
break
end
end
max3=i-l; % Compression only when ND3<1;
NF3=NF3(1:max3);
ND3=ND3(1:max3);
for i=l:max3-1
slopey3(i)=(NF3(i+l)-NF3(i))/(ND3(i+l)-ND3(i));
slopex3(i)=(ND3(i+l)+ND3(i))/2;
end
%if p=l/sqrt(2), ND3=0.2822, and NF3=2.7864
figure (1)
plot(ND1,NFl,'b.',ND2,NF2,'r.',ND3,NF3,'g.');
xlabel('Dimensionless Compression (delta/r)')
ylabel('Dimensionless Force (F*rA2/EI)')
figure (2)
plot(slopexl,slopeyl,'b.',slopex2,slopey2,'r.',slopex3,slopey3,'g.');
xlabel('Dimensionless Compression (delta/r)')
ylabel('Slope of tangent line ((F*rA2/EI)/(delta/r))')
% Axes: Helvetica Font 14
% Label: Microsoft Sans Serif Font 16
function [F,E,Z] = ellipticl2(u,m,tol)
% ELLIPTIC12 evaluates the value of the Incomplete Elliptic Integrals
% of the First, Second Kind and Jacobi's Zeta Function.
% [F,E,Z] = ELLIPTIC12(U,M,TOL) where U is a phase in radians, 0<M<1 is
% the module and TOL is the tolerance (optional). Default value for
% the tolerance is eps = 2.220e-16.
% ELLIPTIC12 uses the method of the Arithmetic-Geometric Mean
% and Descending Landen Transformation described in [1] Ch. 17.6,
% to determine the value of the Incomplete Elliptic Integrals
% of the First, Second Kind and Jacobi's Zeta Function [1], [2].
% F(phi,m) = int(l/sqrt(l-m*sin(t)^2), t=0..phi);
% E(phi,m) = int(sqrt(l1-m*sin(t)^2), t=0..phi);
% Z(phi,m) = E(u,m) - E(m)/K(m)*F(phi,m).
% Tables generating code ([1], pp. 613-621):
% [phi,alpha] = meshgrid(0:5:90, 0:2:90); % modulus
and phase in degrees
% [F,E,Z] = ellipticl2(pi/180*phi, sin(pi/180*alpha) .A2); % values of
integrals
% See also ELLIPKE, ELLIPJ, ELLIPTIC3, THETA, AGM.
% References:
% [1] M. Abramowitz and I.A. Stegun, "Handbook of Mathematical Functions",
% Dover Publications", 1965, Ch. 17.1 - 17.6 (by L.M. Milne-Thomson).
% [2] D. F. Lawden, "Elliptic Functions and Applications"
% Springer-Verlag, vol. 80, 1989
% For support, please reply to
% moiseev[at]sissa.it, moiseev.igor[at]gmail.com
% Moiseev Igor,
% 34106, SISSA, via Beirut n. 2-4, Trieste, Italy
% The code is optimized for ordered inputs produced by the functions
% meshgrid, ndgrid. To obtain maximum performace (up to 30%) for singleton,
% 1-dimensional and random arrays remark call of the function unique(.)
% and edit further code.
if nargin<3, tol = eps; end
if nargin<2, error('Not enough input arguments.'); end
if -isreal(u) | -isreal(m)
error('Input arguments must be real.')
end
length(m)==1, m = m(ones(size(u))); end
length(u)==l, u = u(ones(size(m))); end
-isequal(size(m),size(u)), error('U and M must be the same size.'); end
F = zeros(size(u));
E = F;
Z = E;
m = m(:).'; % make a row vector
u = u(:).';
if any(m < 0) H any(m > 1), error('M must be in the range 0 <= M <= 1.');
end
I = uint32( find(m -= 1 & m
if -isempty(I)
[mu,J,K] = unique(m(I));
K = uint32(K);
mumax = length(mu);
signU = sign(u(I));
% extracts unique values from m
% pre-allocate space and augment if needed
chunk = 7;
a = zeros(chunk,mumax);
c = a;
b = a;
a(l,:) = ones(l,mumax);
c(l,:) = sqrt(mu);
b(l,:) = sqrt(l-mu);
n = uint32( zeros(l,mumax) );
i = 1;
while any(abs(c(i,:)) > tol)
i = i + 1;
if i > size(a,l)
a = [a; zeros(2,mumax)
b = [b; zeros(2,mumax)
c = [c; zeros(2,mumax)
end
a(i,:) = 0.5 * (a(i-l,:) + b(i-1,:))
b(i,:) = sqrt(a(i-l,:) * b(i-l,:));
c(i,:) = 0.5 * (a(i-l,:) - b(i-l,:));
in = uint32( find((abs(c(i,:)) <= tol)
if -isempty(in)
[mi,ni] = size(in);
n(in) = ones(mi,ni)*(i-1);
end
% Arithmetic-Geometric Mean of A, B and C
& (abs(c(i-1, :)) > tol)) );
end
mmax = length(I);
mn = double(max(n));
phin = zeros(l,mmax);
Cp = C; e = uint32(C);
i = 0; c2 = c.A2;
while i < mn
i = i + 1;
in = uint32(find(n(K)
if -isempty(in)
C = zeros(l,mmax);
phin(:) = signU.*u(I);
% Descending Landen Transformation
> i));
phin(in) = atan(b(i,K(in))./a(i,K(in)).*tan(phin(in))) +
pi.*ceil(phin(in)/pi - 0.5) + phin(in);
e(in) = 2.^(i-1) ;
C(in) = C(in) + double(e(in(1)))*c2(i,K(in));
Cp(in)= Cp(in) + c(i+1,K(in)).*sin(phin(in));
end
end
Ff = phin ./ (a(mn,K).*double(e)*2);
F(I) = Ff.*signU; % Incomplete Ell. Int. of the First Kind
Z(I) = Cp.*signU; % Jacobi Zeta Function
E(I) = (Cp + (1 - 1/2*C) .* Ff).*signU;
% Incomplete Ell. Int. of the Second Kind
end
% Special cases: m ={0,1)
mO = find(m == 0);
if -isempty(mO), F(mO) = u(mO); E(mO) = u(mO); Z(mO) = 0; end
ml = find(m == 1);
umi = abs(u(ml));
if -isempty(ml),
N = floor( (uml+pi/2)/pi )
M = find(uml < pi/2);
F(ml(M)) = log(tan(pi/4 + u(ml(M))/2));
F(ml(uml >= pi/2)) = Inf.*sign(u(ml(uml >= pi/2)));
E(ml) = ((-1).^N .* sin(uml) + 2*N).*sign(u(ml));
Z(ml) = (-1).^N .* sin(u(ml));
end
Appendix 2. Control rabbit diet
Laboratory Rabbit Diet HF
DESCRIPTION
Laboratory Rabbit Diet HF (High Fiber) is a complete rabbit
diet tbrmulated for use where research animals are held under
maintenance conditions during the imestigation period and
free-choice feeding is desired. Not intended f~r use when
reproduction, lactation and growth are major goals. Refer to
the Shelf Life section at the end of this book flr product
longeviry information and storae suggestions.
Features and Benefits
* High fiber content alk-ms free-choice feeding without
excessive weight gains
* Nutritionally complete diet
Product Forms Available
SPellet. 4 nmm (5/32") diameter x 10 mm (3/8") length
* Meal (ground pellets). special order
GUARANTEED ANALYSIS
Crude protein not less than .................. .14.9
Crude fat not less than .................. .... 1.5%
Crude fiber not more than .................. .25.0%
Ash not more than .................. ..... . 10."0%
Added minerals not more than .................. 1.5%
INGREDIENTS
Dehydrated alftlfa meal, ground soybean hulls, wheat
middlings, cane mohlasses, dehulled soybean meal ground
corn. dicalcium phosphate, monocalcium phosphate. salt.
porcine animal fat preserved with BHA, calcium carbonate,
DL-methionine. choline chloride, magnesium oxide, vitamin
A acetate, folic acid, cholecakiferol. pyridoxine
hydrochloride, dl-alpha tocopheryl acetate, caklcium
pantothenate, nicotinic acid, riboflavin, cyanocotlamini.
manganous oxide, zinc oxide, cobalt carbonate, ferrous
carbonate, copper sulfate, zinc sulfate, calcium iodate, sodium
selenite.
FEEDING DIRECTIONS
Laboratory Rabbit Diet HF should be fed free-choice
to maintain animals. If animals become obese it may be
necessary to restrict the level of feed intake. Levels of feed
intake of 150-200, grams per day depending on body size and
condition have been used to maintain body weight. Plenty of
clean, fresh water should be available to the
animals at all times.
o i 5s
CHEMICAL COMPOSITION'
Nutrients'
Protein, % .............. 14.8
Arginine,% ............... .0.70
Cxstine, % ............... 0.18
Glycine. % ............... 0.54
Histidine. % .............. 0.38
Isoleucine, % .............. . .75
Leucine,% ............... 0.99
Lysine, % ................ 0.76
Methionine,% ............ 0.33
Phenylalanine. % ........... 0.77
Tyrosine, % ............... 0.57
Threonine.% ............. 0.53
Tryptophan. % ........... 0.2"
Valine.% ................. 0.84
Serine.% ................ .T77
Aspartic Acid % ........... 1.73
Glutamic Acid, % .......... 2.89
Alani ne.% ............. 70
Proline. % ................ 1.16
Taurine. % .............. .<0.01
Fat (ether extract), % ...... 2.3
Fat (acid hydrolysis), % .... .3.5
CholestemrL ppm ... ....... .<10
Linoleic Acid. % ........... 0.84
Linolenic Acid,% ......... 0.24
Arachidonic Acid.% , ...... <0.01
Omega-3 Fatty Acids. % . . . . .0.24
Total Saturated Fatty Acids, % .0.60
Total Monounsaturated
Fatty Acids,% .............. 0.52
Fiber (Crude), % ........ 22.5
Neutral Detergent Fiber'. %.. .41.8
Acid Detergent Fiber', % ..... 27.3
Nitrogen-Free Extract
(by difference), % .......... 42.8
Starch, % ....... ......... . 9.4
Glucose, % ............... 0.27
Fructse.% .............. .0.92
Sucrose, % ............. .3.111
Lactose. % .............. 0-10
Total Digestible Nutrients,% .. 63.2
Gross Energv, kcal/gm ..... 2.95
Phl'siological Fuel Value,
kcal/gn ................. 2.51
Metabolizable Energy,
kcal/gmn ................ .2.01
Minerals
Ash, % .................. 6.8
Calcium,% % .............. 0.95
Phosphorus. % ........... 0.51
Phosphorus (non-phytate), % . .0.33
Potassium, % .............. 1.85
Magnesium, % ............ 0. f
Sulfiur,% ................. .0.23
Sodium,% ............... 0.25
Chlorine, % .............. 0.b 2
Fluorine. ppnm ............. 14
Iron. ppm ................ 40
Zinc. ppm ................ 120
Manganese. ppm ........... 130
Copper, ppm .............. 20
Cobalt ppm ............... 1.7
Iodine. ppm ............. . 1.6
Chromium, ppm ............ 1.4
Selenium. ppm ......... 0.48
Vitamins
Carotene. ppm .............. 18
Vitamin K (as menadione),ppm .3.4
Thiamin Hydrochloride, ppm . .5.3
Ribotlavin, ppm .......... .6.5
Niacin, ppm ............... 52
Pantothenic Acid, ppm ........ 19
Choline Chloride, ppm ..... .160-
Folic Acid. ppm . . ......... 7.4
Pyrid xinre, ppm ............ 4.5
Biotin, ppm .............. (.30
Bt. mn cg kg ............... 7.0
Vitamin A, IU/gmn ......... .20
Vitamin D, (added). IU/gm .... 1.1
Vitamin E. IU/kg ........... 48
Ascorbic Acid, mg/gin ........
Calories provided by:
Protein.% ............ .23.541
Fat (ether extract), % ...... .8.302
Carbohydrates, % ......... 68.157
'Product Code
1. Based on the latest ingredient
analysis information. Since
nutrient composition of natural
ingredients varies, analysis will
dilr accordi .
2.Nutrients expressed as percent of
ration except where otherwise
indicated. Moisture content is
assumed to be 10.(; for the
purpose ofcalculation.
3. NDF = approximately cellulose.
henmi-cellulose and lignin.
4. ADF = apprxidmately cellulose
and lignin.
5. Physiological Fuel Value
tkcal.gm) = Sum of decimal
fractions of protein, fat and carbo-
hydrate (use Nitrogen Free
Extract) x 4.9.4 kcaligm
respectively.
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Appendix 3. Low calcium rabbit diet
Modified LabDiet 5321 wl Reduced Calcium
DESCRIPTION
Modified LabDiett Laboratory Rabbit Diet
5321with Reduced Calcium (0.50 to 0.55% Ca).
Storage conditions are particulartly critical to
TestDietS products, due to the absence of
antioxidants or preservative agents. To provide
maximum protection against Possible changes
during storage, store in a dry, cool location.
Storage under refrigeration (2' C) is
recommended. Maximum shelf life is six months.
(If long term studies are involved, storing the diet
at -20' C or colder may prolong shelf life.) Be
certain to keep in air tight contanersm.
Product Forms Available*
3116" Petlet
Catalog #
1812909
*Other Forms Available On Request
INGREDIENTS
Dehydrated Alfalfa Meal, VWheat Middlings, Ground
Comrn. Ground Oats, Dehuled Soybean Meal
Ground Soybean Hulls, Cane Molasses, Salt. 5S4T
Vitamin & Minerai Premix, Soybean Oi, DL-
Methionine, Dicalcium Phosphate, Choline
Chloride.
FEEDING DIRECTIONS
Feed ad libitum. Plenty of fresh, dean water
should be available at all times.
CAUTION:
Perishable -store upon receipt.
For laboratory animal use only;, not for human
consumption.
1114/2008
NUTRITIONAL PROFILE
Protein, %
Argirnine, %
Histidine. %
isoleucine, %
Leucine, %
Lysine, %
Methionine, %
Cystne, %
Phenyialanine. %
Tyrosine. %
Threonine. %
Tryptophan, %
Vaiine. %
A'anine, %
Aspartic AcJ, %
Glutamic Acid. %
Glyone, %
Proline, %
Serine. %
Taurine, %
Fat (ether extract), %
Fat (acid hydrolysis), %
Cholesterol, ppm
Linoteic Acid, %
Linolenic Acid, %
Arachidonic Acid, %
Omega-3 Fatty Acids, %
Total Saturated Fatty Acids, %
Total Monounsaturated
Fatty Adds, %
Polyunsaturated Fatty Acids, %
Fiber (max), %
Neutral Detergent Fiber2 , %
Acid Detergent Fiber3 , %
Nitrogen-Free Extract
(by difference), %
Starch, %
Glucose, %
Fructose, %
Sucrose, %
Lactose, %
Total Digestible Nutrients, %
Energy (kcal/g) '
From:
Protein
Fat (ether extract)
Carbohydrates
ISI 11:!PI
17.0
0.90
0.40
0.90
1.29
0.80
0.37
0.23
0.82
0.53
0.62
0.21
0.87
0.81
1.78
3.27
0.75
1.30
0.82
0.00
2.8
4.1
0
1.32
0.25
0.00
0.25
0.52
0.61
1.23
14.7
30.6
17.9
48.9
25.51
0.33
0.89
2.39
0.00
65.4
2.89
kcal %
0.680 23.6
0.252 8.7
1.955 67.7
Minerals
Ash, %
Calcium, %
Phosphorus, %
Phosphorus (available), %
Potassium, %
Magnesium, %
Suffur, %
Sodium, %
Chloride. %
Fluorine, ppm
Iron, ppm
Zinc, ppm
Manganese. ppm
Copper, ppm
Cobalt ppm
Iodine, ppm
Chromium, ppm
Selenium, ppm
Vitamins
Carotene. ppm
1Vtanin A. IUg
Vtarrmin D-3 (added), IUIg
V¢tarin E. IU.kg
Vitamin K (as menadione), ppm
Thiamin Hydrochloride, ppm
Ribof avin, ppm
Niacin. ppm
Pantothenic Acid, prn
Folic Acd: ppm
Pyridoxine, ppm
Biotin. ppm
V iamin B-12, mcg/kg
Choline Chloride. ppm
Ascorbic Acid. ppm
6.6
0.51
0.44
0.20
1.20
0.39
0.24
0.30
0.65
3.3
276
120
122
18
1.26
1.61
0.69
0.43
30.7
20
1.1
48
2.9
6
5.5
54
19
8.5
4.50
0.3
7
1,600
0
1. Based on the latest ingredient analysis
information. Since nutrient composition of
natural ingredients varies, analysis will differ
accordingly. Nutrients expressed as percent
of ration on an As-Fed basis except where
otherwise indicated. Moisture content is
assumed to be 10.0% for the purpose of
calcu ations.
2. NDF = approximately cellu ose. herni-
cellutose and lignin.
3. ADF = approximately ceilulose and ignin.
4. Energy (kcal/gm) - Sum of decimal
fractions of protein, fat and carbohydrate x
4,9,4 kcallgm respectively.
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